Anti-HLA-G antibodies and uses thereof

Specific HLA-G antibodies are developed to inhibit ILT2 and ILT4 receptors, addressing cross-reactivity issues with other MHC class I molecules and enhancing immune response restoration for cancer therapy.

JP7592050B2Active Publication Date: 2024-11-29F HOFFMANN LA ROCHE & CO AG
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2022113646
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-11-18
Filing Date
2022-07-15
Publication Date
2024-11-29
Estimated Expiration
2037-11-16

AI Technical Summary

Technical Problem

Existing antibodies targeting HLA-G are not truly specific and often cross-react with other MHC class I molecules, lacking effective receptor blocking properties, which hinders their ability to inhibit HLA-G-mediated immunosuppression in cancer and other pathological conditions.

Method used

Development of HLA-G-specific antibodies that selectively bind to human HLA-G β2M MHC I complexes, inhibiting the interaction with ILT2 and/or ILT4 receptors without cross-reactivity, using stringent screening assays and optimized chimeric antigens to ensure specificity.

Benefits of technology

The developed antibodies effectively inhibit ILT2 and ILT4 binding to HLA-G, restoring immune responses and reducing cross-reactivity with other MHC class I molecules, offering potential therapeutic benefits in cancer treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007592050000012
    Figure 0007592050000012
  • Figure 0007592050000013
    Figure 0007592050000013
  • Figure 0007592050000014
    Figure 0007592050000014
Patent Text Reader

Abstract

Anti-human leukocyte antigen G (HLA-G) antibodies and methods of use thereof are provided. [Solution] Provided are an isolated antibody that specifically binds to human HLA-G, the antibody binding to the human HLA-Gβ2MMHCI complex comprising a specific amino acid sequence, an isolated nucleic acid encoding the antibody, a host cell containing the nucleic acid, and a pharmaceutical formulation comprising the antibody and a pharmaceutically acceptable carrier.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to anti-HLA-G antibodies and methods of using the same. [Background technology]

[0002] Human major histocompatibility complex, class I, 6, also known as human leukocyte antigen G (HLA-G), is a protein that in humans is encoded by the HLA-G gene. HLA-G belongs to the non-classical class I heavy chain paralogs of HLA. This class I molecule is a heterodimer (beta-2 microglobulin) consisting of a heavy chain and a light chain. The heavy chain is anchored in the membrane but can be shed / secreted. The heavy chain consists of three domains: alpha1, alpha2 and alpha3. The alpha1 and alpha2 domains form a peptide-binding groove flanked by two alpha helices. Small peptides (approximately 9-mers) can bind to this groove, as do other MHC I proteins. · The second chain is beta 2 microglobulin which binds to the heavy chain just like other MHC I proteins.

[0003] In the case of HLA-G, seven isoforms exist, three of which are secreted and four of which are membrane-bound (schematically shown in Figure 1).

[0004] HLA-G can form functionally active complex oligomeric structures (Kuroki, K et al. Eur J Immunol. 37(2007)1727-1729). Disulfide-linked dimers are formed between Cys42 of two HLA-G molecules. (Shiroishi M et al., J Biol Chem 281(2006)10439-10447. Trimeric and tetrameric complexes are also described, for example, in Kuroki, K et al. Eur J Immunol. 37(2007)1727-1729, Allan DS, et al. J Immunol Methods. 268(2002)43-50 and T Gonen-Gross et al., J Immunol 171(2003)1343-1351.)

[0005] HLA-G is predominantly expressed in the placental cytotrophoblast. Multiple tumors, including pancreatic, breast, skin, colorectal, gastric, and ovarian, express HLA-G (Lin, A. et al., Mol Med. 21(2015)782-791; Amiot, L., et al., Cell Mol Life Sci. 68(2011)417-431). This expression has also been reported to be associated with pathological conditions such as inflammatory diseases, GvHD, and cancer. HLA-G expression has been reported to be associated with poor cancer prognosis. Tumor cells evade host immune surveillance by inducing immune tolerance / suppression via HLA-G expression. TIFF0007592050000001.tif63170

[0006] HLA-G shares a high degree of homology (>98%) with other MHC I molecules and therefore true HLA-G-specific antibodies without cross-reactivity to other MHC I molecules are difficult to generate.

[0007] Specific antibodies that interact with HLA-G in various ways have been described previously: Tissue Antigens, 55 (2000) 510-518, relates to monoclonal antibodies such as 87G, and MEM-G / 9; Neoplasma 50 (2003) 331-338, relates to specific monoclonal antibodies that recognize both intact HLA-G oligomeric complexes (e.g. 87G and MEM-G9) and heavy chains without HLA-G (e.g. 4H84, MEM-G / 1 and MEM-G / 2); Hum Immunol. 64 (2003) 315-326, relates to several antibodies tested on HLA-G expressing JEG3 tumor cells (e.g. MEM-G / 09 and -G / 13, which react only with native HLA-G1 molecules). MEM-G / 01 recognises denatured HLA-G heavy chains of all isoforms (like 4H84 mAb) and MEM-G / 04 recognises selectively denatured HLA-G1, -G2 and -G5 isoforms; Wiendl et al Brain 2003 176-85 relates to various monoclonal HLA-G antibodies such as 87G, 4H84, MEM-G / 9.

[0008] The above literature reports antibodies that bind to human HLA-G or human HLA-G / β2M MHC complex. However, due to the high polymorphism and high homology of the HLA family, many antibodies lack any truly specific HLA-G binding properties, and even often bind or cross-react with other HLA family members (as MHC complexes with β2M or in their β2M-free forms), or simply do not inhibit the binding of the HLA-G β2M MH complex to its receptors ILT2 and / or ILT4 (and are considered non-antagonist antibodies). Thus, there is a need to generate and / or select truly HLA-G specific antibodies with improved receptor blocking properties. Summary of the Invention

[0009] The present invention provides individually optimized chimeric antigens and / or stringent screening assays to identify HLA-G specific antibodies from a large number of candidates (selecting for HLA-G receptor (e.g. ILT2) blocking antibodies while avoiding cross-reactivity to other MHC class I complex molecules).

[0010] The present invention relates to a monomeric wild-type human HLA-G β2M MHC I complex comprising SEQ ID NO:25; and a monomeric modified HLA-G β2M MHC I complex comprising SEQ ID NO: 26, in which all HLA-G specific amino acids are replaced by HLA consensus amino acids for HLA-A; and ILT2 ILT4 The present invention provides a kit for screening for an antibody specific for the human HLA-G β2M MHC complex that does not cross-react with other HLA-A family proteins and inhibits the binding of HLA-G to one of its receptors, ILT2 and / or ILT4.

[0011] The present invention provides an isolated antibody that binds to human HLA-G, wherein the antibody specifically binds to human HLA-G, and the antibody binds to a human HLA-G β2M MHC I complex comprising SEQ ID NO:25.

[0012] In a preferred embodiment, the anti-HLA-G antibody inhibits binding of ILT2 to the monomeric HLA-G β2M MHC I complex.

[0013] In another preferred embodiment, the anti-HLA-G antibody inhibits binding of ILT2 to monomeric HLA-G β2M MHC I complexes by more than 50% (when compared to binding without the antibody).

[0014] In one embodiment, the anti-HLA-G antibody inhibits binding of ILT2 to monomeric and / or dimeric and / or trimeric HLA-G β2M MHC I complexes by more than 70% (when compared to binding without the antibody).

[0015] In another preferred embodiment, the anti-HLA-G antibody of the present invention binds to human HLA-G on JEG3 cells and inhibits (by more than 50%) the binding of ILT2 to HLA-G on JEG3 cells (when compared to binding without the antibody).

[0016] In one embodiment, the anti-HLA-G antibody does not cross-react with (does not specifically bind to) a modified human HLA-G β2M MHC I complex comprising SEQ ID NO:26.

[0017] In one embodiment, the anti-HLA-G antibody does not cross-react (does not specifically bind to) the mouse H2Kd β2M MHC I complex comprising SEQ ID NO:27 and / or does not cross-react (does not specifically bind to) the rat RT1A β2M MHC I complex comprising SEQ ID NO:29.

[0018] In one embodiment, the anti-HLA-G antibody does not cross-react with (does not specifically bind to) the human HLA-A2 β2M MHC I complex comprising SEQ ID NO:21 and SEQ ID NO:19.

[0019] One embodiment of the invention is an isolated antibody that binds to human HLA-G, A) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:3; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6; or B) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:10; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:11; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:12; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:13; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:14. Includes.

[0020] One embodiment of the invention is an isolated antibody that binds to human HLA-G, A) (a) a VH domain comprising (i) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1, (ii) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2, and (iii) an HVR-H3 comprising an amino acid sequence selected from SEQ ID NO: 3; and (b) a VL domain comprising (i) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (ii) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and (iii) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6; or B) (a) a VH domain comprising (i) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 9, (ii) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10, and (iii) an HVR-H3 comprising an amino acid sequence selected from SEQ ID NO: 11; and (b) a VL domain comprising (i) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12; (ii) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13, and (iii) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14. Includes.

[0021] One embodiment of the invention is an isolated antibody that binds to human HLA-G, A) i) a VH sequence of SEQ ID NO: 7 and a VL sequence of SEQ ID NO: 8; or ii) Humanized variants of VH and VL of the antibody of i). Contains; or B) i) the VH sequence of SEQ ID NO: 15 and the VL sequence of SEQ ID NO: 16; or ii) Humanized variants of VH and VL of the antibody of i). Includes.

[0022] In one embodiment, the anti-HLA-G antibody is of the IgG1 isotype.

[0023] In one embodiment the anti-HLA-G antibody is of the IgG1 isotype containing the mutations L234A, L235A and P329G (numbering according to the EU index of Kabat).

[0024] In one embodiment, the anti-HLA-G antibody according to the invention is a monoclonal antibody.

[0025] In one embodiment, the anti-HLA-G antibody according to the invention is a human, humanized, or chimeric antibody.

[0026] In one embodiment, the anti-HLA-G antibody according to the invention is an antibody fragment that binds to HLA-G.

[0027] In one embodiment, the anti-HLA-G antibody according to the invention is a Fab fragment.

[0028] The present invention provides an isolated nucleic acid encoding any of the antibodies described above.

[0029] The invention provides a host cell comprising the nucleic acid.

[0030] The invention provides a method for producing an antibody comprising culturing a host cell so that the antibody is produced.

[0031] The invention provides a method for producing an antibody as described above, further comprising recovering the antibody from the host cell.

[0032] The invention provides pharmaceutical formulations comprising an antibody described herein and a pharma- ceutically acceptable carrier.

[0033] The present invention provides an antibody as described herein for use as a medicament.

[0034] The present invention provides the antibodies described herein for use in the treatment of cancer.

[0035] The invention provides the use of an antibody as described herein in the manufacture of a medicament. In one embodiment, the medicament is for the treatment of cancer.

[0036] The invention provides a method of treating an individual with cancer comprising administering to said individual an effective amount of an antibody described herein.

[0037] The screening method according to the invention allows the selection of novel anti-HLA-G antibodies. Such antibodies show highly useful properties, such as strong inhibition of ILT2 binding to HLA-G expressed on JEG3 cells, or inhibition of ILT2 binding to monomeric and / or dimeric and / or trimeric HLA-G β2M MHC I complexes. Furthermore, the antibodies according to the invention are able to restore suppressed immune responses (i.e. restoration of LPS-induced TNFα production by monocytes in co-culture with HLA-G expressing cells). In addition, the antibodies are highly specific and do not show cross-reactivity with HLA-A MHC I complexes or MHC I complexes of mouse or rat origin. [Brief description of the drawings]

[0038] [Figure 1] The various isoforms of HLA-G are shown. [Figure 2A] FIG. 1 is a schematic diagram of HLA-G with β2M associated molecules. [Figure 2B] Structure of HLA-G molecule associated with specific receptors: HLA-G structure in complex with given receptors: ILT4 and KIR2DL1. ILT4 structure (PDB code: 2DYP). KIR2DL1 structure was taken from PDB code 1IM9 (KIR2DL1:HLA-Cw4 complex structure) and placed on top of HLA-G by superimposing HLA-Cw4 and HLA-G structures. Receptors are represented as ribbons and HLA-G is represented on the molecular surface. HLA-G residues unique to other HLA paralogs or conserved in such paralogs are shown in white and grey, respectively. Unique surface residues were replaced by HLA consensus sequences in the chimeric counter antigen. [Figure 3A]SPR sensorgrams of binding of HLA-G antibodies (HLA-G-0032 and HLA-G-0033) to recombinant HLA-G (SEQ ID NO: 25) and to a control modified human HLA-G β2M MHC class I complex in which HLA-G specific amino acids have been replaced by HLA-A consensus amino acids (=HLA-G degrafted, SEQ ID NO: 26). [Figure 3B] SPR sensorgrams of binding of HLA-G antibodies (HLA-G-0036 and HLA-G-0037) to recombinant HLA-G (SEQ ID NO: 25) and to a control modified human HLA-G β2M MHC class I complex in which HLA-G specific amino acids have been replaced by HLA-A consensus amino acids (=HLA-G degrafted, SEQ ID NO: 26). [Figure 4A] HLA-G antibodies that inhibit (or stimulate) the interaction / binding of HLA-G to ILT2. [Figure 4B] An HLA-G antibody that inhibits (or stimulates) the interaction / binding of HLA-G to ILT4. [Figure 5A] 1 shows flow cytometry analysis of cell surface expression of HLA-G (HLA-G-0032 (#0032)) using an HLA-G antibody on JEG3 (cells naturally expressing HLA-G), SKOV-3 cells (wild type (wt) vs. HLAG transfected cells (HLAG+)), and PA-TU-8902 cells (wild type (wt) vs. HLAG transfected cells (HLAG+)). [Figure 5B] 1 shows flow cytometry analysis of cell surface expression of HLA-G (HLA-G-0033 (#0033)) using an HLA-G antibody on JEG3 (cells that naturally express HLA-G), SKOV-3 cells (wild type (wt) vs. HLAG transfected cells (HLAG+)), and PA-TU-8902 cells (wild type (wt) vs. HLAG transfected cells (HLAG+)). [Figure 5C]1 shows flow cytometry analysis of cell surface expression of HLA-G (HLA-G-0036 (#0036)) using an HLA-G antibody on JEG3 (cells that naturally express HLA-G), SKOV-3 cells (wild type (wt) vs. HLAG transfected cells (HLAG+)), and PA-TU-8902 cells (wild type (wt) vs. HLAG transfected cells (HLAG+)). [Figure 5D] 1 shows flow cytometry analysis of cell surface expression of HLA-G (HLA-G-0037 (#0037)) using an HLA-G antibody on JEG3 (cells naturally expressing HLA-G), SKOV-3 cells (wild type (wt) vs. HLAG transfected cells (HLAG+)), and PA-TU-8902 cells (wild type (wt) vs. HLAG transfected cells (HLAG+)). [Figure 6A] Anti-HLA-G antibodies block / modulate the interaction of human ILT2 Fc chimera with HLA-G expressed on JEG3 cells. Staining of cell surface HLA-G by novel anti-HLA-G antibodies was assessed by using anti-rat IgG secondary antibody conjugated to Alexa488 (a). FACS histograms show cells stained with secondary antibody only (grey dotted line) and with anti-HLA-G antibody (black solid line). The bottom row (b) shows a comparison of human ILT2-Fc bound to HLA-G on JEG3 cells (black dotted line) and cells stained with secondary antibody only (grey dotted line). The effect of pre-incubating JEG3 cells with HLA-G antibodies on ILT2 Fc chimera binding can be seen (black solid line): HLA-G-0032 and HLA-G-0037 show almost complete inhibition of ILT2-Fc chimera binding to JEG3 cells. [Figure 6B]The effect of commercial / standard anti-HLA-G antibodies on the binding of ILT2 Fc chimera to HLA-G on JEG3 cells is shown: staining of cell surface HLA-G by commercial / standard anti-HLA-G antibodies was assessed by using species-specific secondary antibodies conjugated to Alexa488 (a). FACS histograms show cells stained with secondary antibody only (grey dotted line) and with anti-HLA-G antibody (black solid line). The bottom row (b) shows a comparison of human ILT2-Fc chimera binding to HLA-G on JEG3 cells (black dotted line) and cells stained with secondary antibody only (grey dotted line). The effect of pre-incubating JEG3 cells with standard antibodies on ILT2 Fc chimera binding can be seen (black solid line): none of the reference antibodies tested was able to block the interaction of ILT2 Fc chimera with cell surface HLA-G on JEG3 cells. [Figure 7A] 1 shows the effect of blocking HLA-G with inhibitory anti-HLA-G antibodies on the recovery of TNFα-producing donor #1. [Figure 7B] 1 shows the effect of blocking HLA-G with inhibitory anti-HLA-G antibodies on the recovery of TNFα-producing donor #2. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0039] As used herein, the term "HLA-G", "human HLA-G" refers to HLA-G human major histocompatibility complex, class I, G, also known as human leukocyte antigen G (HLA-G) (exemplary SEQ ID NO: 17). Typically, HLA-G forms an MHC class I complex with β2 microglobulin (B2M or β2m). In one embodiment, HLA-G refers to the MHC class I complex of HLA-G and β2 microglobulin.

[0040] As used herein, an antibody that "binds to human HLA-G," "specifically binds to human HLA-G," "binds to human HLA-G," or "anti-HLA-G antibody" refers to an antibody that binds to the human HLA-G antigen or its extracellular domain (ECD) with a specific binding affinity of 5.0×10 -8 K in mol / l D value, in one embodiment, 1.0×10 -9 K in mol / l D value, in one embodiment, 5.0×10 -8 mol / l to 1.0 x 10 -13 K in mol / l D "HLA-G" refers to an antibody that specifically binds with a binding affinity of a certain value. The binding affinity is determined by a standard binding assay, such as surface plasmon resonance (BIAcore®, GE-Healthcare Uppsala, Sweden), using a construct that includes the HLA-G extracellular domain (e.g., its naturally occurring three-dimensional structure). In one embodiment, the binding affinity is determined by a standard binding assay using an exemplary soluble HLA-G containing MHC class I complex that includes SEQ ID NO:25.

[0041] HLA-G has a regular MHC I fold and consists of two chains: chain 1 consists of three domains, alpha1, alpha2 and alpha3. The alpha1 and alpha2 domains form a peptide-binding groove flanked by two alpha helices. Small peptides (approximately 9 mers) can bind to this groove as well as other MHCI proteins. Chain 2 is beta2 microglobulin shared with various other MHCI proteins.

[0042] HLA-G can form functionally active complex oligomeric structures (Kuroki, K et al. Eur J Immunol. 37(2007)1727-1729). Disulfide-bonded dimers are formed between Cys42 of two HLA-G molecules. (Shiroishi M et al., J Biol Chem 281(2006)10439-10447. Trimeric and tetrameric complexes have also been described, for example, in Kuroki, K et al. Eur J Immunol. 37(2007)1727-1729, Allan DS, et al. J Immunol Methods. 268(2002)43-50 and T Gonen-Gross et al., J Immunol 171(2003)1343-1351.) HLA-G, unlike many other MHC class I molecules, has multiple free cysteine ​​residues. Boyson et al., Proc Nat Acad Sci USA, 99: 16180 (2002) reported that recombinant soluble forms of HLA-G5 can form disulfide-linked dimers with intermolecular Cys42-Cys42 disulfide bonds. In addition, membrane-bound forms of HLA-G1 can also form disulfide-linked dimers on the cell surface of the Jeg3 cell line, which endogenously expresses HLA-G. Disulfide-linked dimeric forms of HLA-G1 and HLA-G5 were also found on the cell surface of tophoblast cells (Apps, R., Tissue Antigens, 68:359 (2006)).

[0043] HLA-G is predominantly expressed in the placental cytotrophoblast. Multiple tumors, including pancreatic, breast, skin, colorectal, gastric, and ovarian, express HLA-G (Lin, A. et al., Mol Med. 21(2015)782-791; Amiot, L., et al., Cell Mol Life Sci. 68(2011)417-431). This expression has also been reported to be associated with pathological conditions such as inflammatory diseases, GvHD, and cancer. HLA-G expression has been reported to be associated with poor cancer prognosis. Tumor cells evade host immune surveillance by inducing immune tolerance / suppression via HLA-G expression.

[0044] In the case of HLA-G, seven isoforms exist, three of which are secreted and four are membrane-bound (schematically shown in FIG. 1). The most important functional isoforms of HLA-G include the b2-microglobulin-binding HLA-G1 and HLA-G5. However, the tolerogenic immunological effects of these isoforms are distinct and vary depending on the form of the ligand (monomer, dimer) and the affinity of the ligand-receptor interaction.

[0045] HLA-G protein can be produced using standard molecular biology techniques. The nucleic acid sequences of HLA-G isoforms are known in the art. See, for example, GENBANK Accession No. AY359818.

[0046] HLA-G allotypes promote signaling by ILTs, particularly ILT2, ILT4, or a combination thereof.

[0047] ILTs: ILTs represent Ig-type activating and inhibitory receptors that are involved in regulating immune cell activation and control immune cell function (Borges, L., et al., Curr Top Microbial Immunol, 244:123-136(1999)). ILTs are classified into three groups: (i) inhibitory ones (ILT2, ILT3, ILT4, ILT5, and LIR8) that contain a cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM) and transmit inhibitory signals; (ii) activating ones (ILT1, ILT7, ILT8, and LIR6alpha) that contain a short cytoplasmic tail and charged amino acid residues in the transmembrane domain and deliver activation signals through the cytoplasmic immunoreceptor tyrosine-based activation motif (ITAM) of the binding common gamma chain of Fc receptors; and (iii) a soluble molecule, ILT6, that lacks a transmembrane domain. Many recent studies have highlighted the immunoregulatory role of ILTs on the surface of antigen-presenting cells (APCs). The best-characterized immunoinhibitory receptors, ILT2, ILT3, and ILT4 receptors, are predominantly expressed on myeloid and plasmacytoma DCs. ILT3 and ILT4 are upregulated by exposure of immature DCs to known immunosuppressants, including IL-10, vitamin D3, or suppressor CD8 T cells (Chang, CC, et al., Nat Immunol, 3:237-243(2002)). Expression of ILTs on DCs is tightly regulated by inflammatory stimuli, cytokines, and growth factors, and is downregulated following DC activation (Ju, XS, et al., Gene, 331:159-164(2004)). Expression of the ILT2 and ILT4 receptors is highly regulated by histone acetylation, which contributes to tightly controlled gene expression that is restricted to the myeloid lineage of cells (Nakajima, H., J Immunol, 171:6611-6620(2003)).

[0048] Engagement of the inhibitory receptors ILT2 and ILT4 can alter the cytokine and chemokine secretion profile of monocytes and inhibit Fc receptor signaling (Colonna, M., et al. J Leukoc Biol, 66:375-381(1999)). The role and function of ILT3 on DCs has been described in detail by the Suciu-Foca group (Suciu-Foca, N., Int Immunopharmacol, 5:7-11(2005)). The ligand for ILT3 is unknown, but ILT4 is known to bind to the third domain of HLA class I molecules (HLA-A, HLA-B, HLA-C, and HLA-G) and compete with CD8 for MHC class I binding (Shiroishi, M., Proc Natl Acad Sci USA, 100:8856-8861(2003)). The preferential ligand for several inhibitory ILT receptors is HLA-G. HLA-G plays a potential role in maternal-fetal tolerance and as a mechanism for tumor cell escape from immune recognition and destruction (Hunt, JS, et al., Faseb J, 19:681-693(2005)). Modulation of DC function by HLA-G-ILT interactions is very likely an important pathway in DC biology. It was determined that human monocyte-derived DCs highly expressing ILT2 and ILT4 receptors still maintained a stable tolerogenic-like phenotype (CD80low, CD86low, HLA-DRlow) and had the ability to induce T cell anergy when treated with HLA-G and stimulated with allogeneic T cells (Ristich, V., et al., Eur J Immunol, 35:1133-1142(2005)). Furthermore, interaction of HLA-G with DCs, which highly express ILT2 and ILT4 receptors, led to downregulation of multiple genes involved in the MHC class II presentation pathway. IFN-gamma-inducible lysosomal thiol reductase (GILT), a lysosomal thiol reductase abundantly expressed by professional APCs, was significantly reduced in HLA-G-modified DCs.The repertoire of primed CD4+ T cells may be influenced by DC expression of GILT, as in vivo T cell responses to selected antigens were reduced in animals lacking GILT after targeted gene disruption (Marie, M., et al., Science, 294:1361-1365(2001)). HLA-G / ILT interactions on DCs may interfere with the assembly and trafficking of MHC class II molecules to the cell surface, which may reduce the efficiency of presentation or expression of structurally abnormal MHC class II molecules. It has been determined that HLA-G significantly reduces the transcription of invariant chain (CD74), HLA-DMA, and HLA-DMB genes on human monocyte-derived DCs that highly express ILT inhibitory receptors (Ristich, V., et al; Eur J Immunol 35:1133-1142(2005)).

[0049] Another receptor for HLA-G is KIR2DL4, as KIR2DL4 binds to cells expressing HLA-G (US Patent Application Publication No. 2003232051; Cantoni, C. et al. Eur J Immunol 28(1998)1980; Rajagopalan, S. and EO Long. [Errata in J Exp Med 191(2000)2027] J Exp Med 189(1999)1093; Ponte, M. et al. PNAS USA 96(1999)5674). KIR2DL4 (also called 2DL4) is a member of the KIR family (also named CD158d) that shares structural features with both activating and inhibitory receptors (Selvakumar, A. et al. Tissue Antigens 48(1996)285). 2DL4 has a cytoplasmic ITIM suggesting an inhibitory function and positively charged amino acids in the transmembrane domain, a feature typical of activating KIRs. Unlike other clonally distributed KIRs, 2DL4 is transcribed by all NK cells (Valiante, NM et al. Immunity 7(1997)739; Cantoni, C. et al. Eur J Immunol 28(1998)1980; Rajagopalan, S. and EO Long. [J Exp Med 191(2000)2027] Erratum in J Exp Med 189(1999)1093).

[0050] As used herein, an anti-HLA-G antibody that "does not cross-react with" or "does not specifically bind to" a modified human HLA-G β2M MHC I complex comprising SEQ ID NO:26; a mouse H2Kd β2M MHC I complex comprising SEQ ID NO:27; a rat RT1A β2M MHC I complex comprising SEQ ID NO:29; a human HLA-A2 β2M MHC I complex comprising SEQ ID NO:21 and SEQ ID NO:19 refers to an anti-HLA-G antibody that does not substantially bind to any of these counter antigens. In one embodiment, an anti-HLA-G antibody that "does not cross-react with" or "does not specifically bind to" a modified human HLA-G β2M MHC I complex comprising SEQ ID NO:26; a mouse H2Kd β2M MHC I complex comprising SEQ ID NO:27; a rat RT1A β2M MHC I complex comprising SEQ ID NO:29; and / or a human HLA-A2 β2M MHC I complex comprising SEQ ID NO:21 and SEQ ID NO:19 is an antibody that does not substantially bind to any of these counter antigens. -6 K in mol / l or more D This refers to anti-HLA-G antibodies that only show non-specific binding with a binding affinity of the value (until further binding affinity is undetectable). The binding affinity is determined using standard binding assays such as surface plasmon resonance (BIAcore®, GE-Healthcare Uppsala, Sweden) for the respective antigens, i.e. modified human HLA-G β2M MHC I complex with SEQ ID NO: 26; mouse H2Kd β2M MHC I complex with SEQ ID NO: 27, rat RT1A β2M MHC I complex with SEQ ID NO: 29, and / or human HLA-A2 β2M MHC I complex with SEQ ID NO: 21 and SEQ ID NO: 19. The assay setup and antigen construction / preparation are described in the Examples.

[0051] An "acceptor human framework" for purposes herein is a framework that contains the amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework obtained from a human immunoglobulin framework or a human consensus framework, as defined below. An acceptor human framework "derived from" a human immunoglobulin framework or a human consensus framework may contain the same amino acid sequence or may contain changes in the amino acid sequence. In some embodiments, the number of amino acid changes is 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the VL acceptor human framework is identical in sequence to the VL human immunoglobulin framework sequence or the human consensus framework sequence. (Specifying germline where appropriate)

[0052] The term "antibody" is used in the broadest sense and encompasses a variety of antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, so long as they exhibit the desired antigen-binding activity.

[0053] "Antibody fragment" refers to a molecule other than an intact antibody that contains a portion of an intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments.

[0054] An "antibody that binds to the same epitope" as a reference antibody refers to an antibody that blocks the binding of the reference antibody to its antigen by 50% or more in a competitive assay, and conversely, the reference antibody blocks the binding of the antibody to its antigen by 50% or more in a competitive assay. Exemplary competitive assays are provided herein.

[0055] The term "chimeric" antibody refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular origin or species, and the remainder of the heavy and / or light chain is derived from a different origin or species.

[0056] The "class" of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these can be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IGA1, and IgA2. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.

[0057] The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents the function of a cell and / or causes cell death or destruction. Cytotoxic agents include, but are not limited to, radioisotopes (e.g., At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32, Pb212, and radioisotopes of Lu); chemotherapeutic agents or drugs (e.g., methotrexate, adriamycin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin, or other intercalating agents); growth inhibitors; enzymes and fragments thereof, such as nucleases; antibiotics; toxins, such as small molecule toxins, or enzymatically active toxins of bacterial, fungal, plant, or animal origin, including fragments and / or variants thereof, and various antitumor or anticancer agents disclosed below.

[0058] An "effective amount" of an agent, e.g., a pharmaceutical formulation, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.

[0059] As used herein, the term "Fc region" is used to define a C-terminal region of an immunoglobulin heavy chain, including at least a portion of the constant region. This term includes native sequence Fc regions and variant Fc regions. In one embodiment, a human IgG heavy chain Fc region extends from Cys226 or Pro230 to the carboxyl terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region, or the C-terminal glycine (Gly446) and the C-terminal lysine (Lys447) may be present or absent. Unless otherwise specified, numbering of amino acid residues within the Fc region or constant region is according to the EU numbering system, also referred to as the EU index, as described in Kabat, EA et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD(1991), NIH Publication 91-3242.

[0060] "Framework" or "FR" refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain is generally composed of four FR domains, namely FR1, FR2, FR3, and FR4. Thus, the HVR and FR sequences generally appear in the following sequence in VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.

[0061] The terms "full length antibody," "intact antibody," and "whole antibody" are used interchangeably herein and refer to an antibody having a structure substantially similar to a native antibody structure or having a heavy chain that includes an Fc region as defined herein.

[0062] The terms "host cell," "host cell line," and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells," which include the primary transformed cell and its progeny, regardless of the number of passages. The progeny may not be completely identical in nucleic acid content as the parent cell and may contain mutations. Included herein are mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell.

[0063] A "human antibody" is one having an amino acid sequence that corresponds to that of an antibody produced by a human or human cell, or derived from a non-human source that utilizes the human antibody repertoire or other human antibody-encoding sequences. This definition of human antibody specifically excludes humanized antibodies which contain non-human antigen-binding residues.

[0064] A "human consensus framework" is a framework that represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Typically, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Typically, the subgroup of sequences is a subgroup of Kabat, EA et al., Sequences of Proteins of Immunological Interest, 5th ed., Bethesda MD(1991), NIH Publication 91-3242, Vols. 1-3. In one embodiment, the VL subgroup is subgroup kappa I in Kabat et al., supra. In one embodiment, the VH subgroup is subgroup III in Kabat et al., supra.

[0065] A "humanized" antibody refers to a chimeric antibody that comprises amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody comprises substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody and all or substantially all of the FRs correspond to those of a human antibody. A humanized antibody may optionally comprise at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization.

[0066] The term "hypervariable region" or "HVR" as used herein refers to each of the regions of an antibody variable domain that are hypervariable in sequence ("complementarity determining regions" or "CDRs") and / or that form structurally defined loops ("hypervariable loops") and / or that contain residues that contact the antigen ("antigen contacts"). Typically, an antibody contains six HVRs, three in the VH (H1, H2, H3) and three in the VL (L1, L2, L3). Exemplary HVRs herein are: (a) hypervariable loops occurring at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987)); (b) CDRs occurring at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991)); (c) antigenic contacts occurring at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al. J. Mol. Biol. 262: 732-745 (1996)); and (d) combinations of (a), (b), and / or (c), including HVR amino acid residues 46-56 (L2), 47-56 (L2), 48-56 (L2), 49-56 (L2), 26-35 (H1), 26-35b (H1), 49-65 (H2), 93-102 (H3), and 94-102 (H3). Includes.

[0067] Unless otherwise specified, HVR residues and other residues in the variable domain (e.g., FR residues) are numbered herein according to Kabat et al., supra.

[0068] An "immunoconjugate" is an antibody conjugated to one or more heterologous molecules, including, but not limited to, a cytotoxic agent.

[0069] An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domestic animals (e.g., cows, sheep, cats, dogs, horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the individual or subject is a human.

[0070] An "isolated" antibody is one that has been separated from components of its natural environment. In some embodiments, the antibody is purified to greater than 95% or 99% purity, for example, as determined by electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reverse-phase HPLC). For a review of methods for assessing antibody purity, see, for example, Flatman, S., et al., J. Chromatogr. B 848(2007)79-87.

[0071] An "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. Isolated nucleic acid includes a nucleic acid molecule contained in a cell that normally contains the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or in a chromosomal location that is different from its natural chromosomal location.

[0072] An "isolated nucleic acid encoding an anti-HLA-G antibody" refers to one or more nucleic acid molecules encoding the antibody heavy and light chains (or fragments thereof), including such nucleic acid molecules in a single vector or separate vectors, and including such nucleic acid molecules present in one or more locations in a host cell.

[0073] The term "monoclonal antibody" as used herein means an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and / or bind to the same epitope, except for variant antibodies that may contain naturally occurring mutations or arise during the manufacture of the monoclonal antibody preparation and are generally present in minor amounts. In contrast to polyclonal antibody preparations, which typically contain different antibodies against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier "monoclonal" indicates the character of the antibody as being obtained from a population of substantially homogeneous antibodies and should not be construed as requiring production of the antibody by any particular method. For example, monoclonal antibodies used in accordance with the present invention can be produced by a variety of techniques, including, but not limited to, hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, and these and other exemplary methods for producing monoclonal antibodies are described herein.

[0074] "Naked antibody" refers to an antibody that is not conjugated to a heterologous moiety (e.g., a cytotoxic moiety) or radiolabel. The naked antibody may be present in a pharmaceutical formulation.

[0075] "Native antibodies" refer to naturally occurring immunoglobulin molecules with various structures. For example, native IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons consisting of two identical light chains and two identical heavy chains that are disulfide-bonded. Each heavy chain has, from N-terminus to C-terminus, a variable region (VH), also called a variable heavy domain or heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3). Similarly, each light chain has, from N-terminus to C-terminus, a variable region (VL), also called a variable light domain or light chain variable domain, followed by one constant light (CL) domain. The light chain of an antibody can be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of its constant domain.

[0076] The term "package insert" is used to refer to instructions customarily included in the commercial packaging of a therapeutic product, which contain information about the indications, usage, dosage, administration, concomitant therapy, contraindications and / or precautions regarding the use of such therapeutic product.

[0077] "Percent (%) amino acid sequence identity" with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to those in the reference polypeptide, after aligning the sequences and introducing gaps, if necessary, to obtain the maximum percent sequence identity, with any conservative substitutions not being considered part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be accomplished by a variety of methods within the skill of the art, such as using publicly available computer software, such as BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms required to achieve maximum alignment over the full length of the sequences being compared. However, for purposes herein, % amino acid sequence identity values ​​are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was created by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington, DC, 20559, and is registered under U.S. Copyright Registration No. TXU510087. ALIGN-2 is publicly available from Genentech, Inc. (South San Francisco, California) or may be compiled from its source code. The ALIGN-2 program should be compiled for use on UNIX operating systems, including Digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

[0078] In the context of using ALIGN-2 for amino acid sequence comparison, the % amino acid sequence identity of a given amino acid sequence A with or against a given amino acid sequence B (alternatively, one may say a given amino acid sequence A has or contains % amino acid sequence identity with or against a given amino acid sequence B) is calculated as follows: 100 × fraction X / Y where X is the number of amino acid residues scored as identical by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and Y is the total number of amino acid residues in B. It will be understood that if the length of amino acid sequence A is different from the length of amino acid sequence B, then the % amino acid sequence identity of A to B will differ from the % amino acid sequence identity of B to A. Unless otherwise specified, all % amino acid sequence identity values ​​used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.

[0079] The term "pharmaceutical formulation" refers to a preparation that is in a form that allows the biological activity of the active ingredient contained therein to be effective and that does not contain other ingredients that are unacceptably toxic to the subject to which the formulation is administered.

[0080] "Pharmaceutically acceptable carrier" refers to an ingredient of a pharmaceutical formulation, other than an active ingredient, that is non-toxic to a subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.

[0081] As used herein, "treatment" (and grammatical variations such as "treat" or "treating") refers to a clinical intervention that attempts to alter the natural course of the individual being treated, and can be performed for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing the onset or recurrence of disease, alleviating symptoms, reducing direct or indirect pathological consequences of the disease, preventing metastasis, slowing the rate of disease progression, improving or mitigating the disease state, and remission or improving prognosis. In some embodiments, the antibodies of the invention are used to delay the onset of disease or slow the progression of disease.

[0082] The term "variable region" or "variable domain" refers to the domain of an antibody heavy or light chain involved in binding the antibody to an antigen. The heavy and light chain variable domains (VH and VL, respectively) of natural antibodies generally have a similar structure, each containing four conserved framework regions (FR) and three hypervariable regions (HVR). (See, e.g., Kindt, TJ et al. Kuby Immunology, 6th ed., WH Freeman and Co., NY (2007), page 91.) A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind to a particular antigen can be isolated using a VH or VL domain derived from an antibody that specifically binds to that antigen, and a library of complementary VL or VH domains, respectively, can be screened. See, e.g., Portolano, S. et al., J. Immunol. 150(1993)880-887; Clackson, T. et al., Nature 352(1991)624-628).

[0083] The term "vector" as used herein refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes vectors as self-replicating nucleic acid structures as well as vectors integrated into the genome of a host cell into which they are introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as "expression vectors."

[0084] I. Compositions and Methods In one aspect, the invention is based in part on the discovery that selected anti-HLA-G antibodies of the invention have the ability to bind to specific epitopes of HLA-G and inhibit the binding of ILT2 and / or ILT4 to HLA-G, e.g., by inhibiting the binding of ILT2 to HLA-G and increasing the secretion of immunomodulatory cytokines such as TNF-alpha upon appropriate stimulation, thereby reversing HLA-G mediated immunosuppression.

[0085] In certain embodiments, antibodies are provided that bind to HLA-G. The antibodies of the invention are useful, for example, in the diagnosis or treatment of cancer.

[0086] A. Exemplary Anti-HLA-G Antibodies In one aspect, the invention provides an isolated antibody that binds to human HLA-G (anti-HLA-G antibody).

[0087] In a particular embodiment, an isolated antibody that specifically binds to human HLA-G is provided that binds to the human HLA-G β2M MHC I complex comprising SEQ ID NO:25 (see Example 3).

[0088] In a particular embodiment, an isolated antibody that specifically binds to human HLA-G is provided that binds to a human HLA-G β2M MHC I complex comprising SEQ ID NO:25 and inhibits binding of ILT2 to a monomeric HLA-G β2M MHC I complex (see, e.g., Examples 4a and 4b).

[0089] In a particular embodiment, an isolated antibody that specifically binds to human HLA-G is provided that binds to the human HLA-G β2M MHC I complex (comprising SEQ ID NO: 25) and inhibits binding of ILT2 to the monomeric HLA-G β2M MHC I complex by more than 50% (when compared to binding without the antibody) (see, e.g., Example 4b).

[0090] In a particular embodiment, an isolated antibody that specifically binds to human HLA-G is provided which binds to the human HLA-G β2M MHC I complex (comprising SEQ ID NO: 25) and inhibits binding of ILT2 to monomeric and / or dimeric and / or trimeric HLA-G β2M MHC I complexes by more than 50% (in one embodiment by more than 70%) (when compared to binding without the antibody) (see, e.g., Example 4b).

[0091] In a particular embodiment, an isolated antibody that specifically binds to human HLA-G is provided which binds to the human HLA-G β2M MHC I complex (comprising SEQ ID NO: 25) and inhibits binding of ILT2 to monomeric and / or dimeric and / or trimeric HLA-G β2M MHC I complexes by more than 60% (compared to binding without the antibody) and inhibits binding of ILT4 to dimeric and / or trimeric HLA-G β2M MHC I complexes by more than 50% (compared to binding without the antibody) (see e.g. Example 4b).

[0092] In a particular embodiment, an isolated antibody that specifically binds to human HLA-G is provided that binds to the human HLA-G β2M MHC I complex comprising SEQ ID NO: 25 and inhibits binding of ILT2 and ILT4 to the HLA-G β2M MHC I complex (see, e.g., Example 4).

[0093] In a particular embodiment, an isolated antibody that specifically binds to human HLA-G is provided which binds to the human HLA-G β2M MHC I complex (comprising SEQ ID NO: 25) and inhibits (by more than 50%, in one embodiment by more than 80%) binding of ILT2 to JEG3 cells (HLA-G above) (ATCC No. HTB36) (when compared to binding without the antibody) (see Example 6).

[0094] In a particular embodiment, an isolated antibody that specifically binds to human HLA-G is provided which binds to JEG3 cells (ATCC No. HTB36) (see Example 5) and inhibits (by more than 50%, in one embodiment by more than 80%) the binding of ILT2 to HLA-G (ATCC No. HTB36) on JEG3 cells (when compared to binding without the antibody) (see Example 6).

[0095] In certain embodiments, the anti-HLA-G antibodies described herein do not cross-react with (do not specifically bind to) a modified human HLA-G β2M MHC I complex comprising SEQ ID NO:26.

[0096] In certain embodiments, the anti-HLA-G antibodies described herein do not cross-react (do not specifically bind to) the mouse H2Kd β2M MHC I complex comprising SEQ ID NO:27 and / or do not cross-react (do not specifically bind to) the rat RT1A β2M MHC I complex comprising SEQ ID NO:29.

[0097] In certain embodiments, the anti-HLA-G antibodies described herein do not cross-react with (do not specifically bind to) the human HLA-A2 β2M MHC I complex comprising SEQ ID NO:21 and SEQ ID NO:19.

[0098] One embodiment of the invention is an isolated antibody that binds to human HLA-G, the antibody comprising: A) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:3; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6; or B) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:10; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:11; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:12; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:13; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:14. Includes.

[0099] One embodiment of the invention is an isolated antibody that binds to human HLA-G, the antibody comprising: A) (a) a VH domain comprising (i) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1, (ii) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2, and (iii) an HVR-H3 comprising an amino acid sequence selected from SEQ ID NO: 3; and (b) a VL domain comprising (i) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (ii) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and (iii) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6; or B) (a) a VH domain comprising (i) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 9, (ii) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10, and (iii) an HVR-H3 comprising an amino acid sequence selected from SEQ ID NO: 11; and (b) a VL domain comprising (i) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12; (ii) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13, and (iii) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14. Includes.

[0100] One embodiment of the invention is an isolated antibody that binds to human HLA-G, the antibody comprising: A) i) a VH sequence of SEQ ID NO: 7 and a VL sequence of SEQ ID NO: 8; or ii) comprising humanized variants of the VH and VL of the antibody of i); or B) i) the VH sequence of SEQ ID NO: 15 and the VL sequence of SEQ ID NO: 16; or ii) Humanized variants of VH and VL of the antibody of i). Includes.

[0101] One embodiment of the invention is an anti-HLA-G antibody as described herein, which is independently characterized by the following properties: a) competes for binding to HLA-G with an anti-HLA-G antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:7 and a VL comprising the amino acid sequence of SEQ ID NO:8; and / or b) binds to the same epitope as an anti-HLA-G antibody comprising a VH comprising the amino acid sequence of SEQ ID NO: 7 and a VL comprising the amino acid sequence of SEQ ID NO: 8, and / or c) binds to a human HLA-G β2M MHC I complex comprising SEQ ID NO: 25; and / or d) does not cross-react with (does not specifically bind to) a modified human HLA-G β2M MHC I complex comprising SEQ ID NO: 26; and / or e) does not cross-react with (does not specifically bind to) the human HLA-A2 β2M MHC I complex comprising SEQ ID NO:21 and SEQ ID NO:19; and / or f) does not cross-react with (does not specifically bind to) the mouse H2Kd β2M MHC I complex containing SEQ ID NO: 27; and / or g) does not cross-react with (does not specifically bind to) the rat RT1A β2M MHC I complex containing SEQ ID NO: 29; and / or h) inhibiting binding of ILT2 to a monomeric HLA-G β2M MHC I complex (comprising SEQ ID NO: 25); and / or i) inhibits binding of ILT2 to a monomeric HLA-G β2M MHC I complex (comprising SEQ ID NO: 25) by more than 50% (in one embodiment by more than 70%) (when compared to binding without the antibody); and / or j) inhibits the binding of ILT2 to monomeric and / or dimeric and / or trimeric HLA-G β2M MHC I complexes (comprising SEQ ID NO: 25) by more than 50% (in one embodiment by more than 70%) (when compared to binding without the antibody); and / or k) inhibits (by more than 50%, in one embodiment by more than 80%) the binding of ILT2 to JEG3 cells (HLA-G above) (ATCC No. HTB36) (when compared to binding without the antibody) (see Example 6); and / or l) binds to JEG3 cells (HLA-G above) (ATCC No. HTB36) (see Example 5) and inhibits (by more than 50%, in one embodiment by more than 80%) the binding of ILT2 to JEG3 cells (HLA-G above) (ATCC No. HTB36) (when compared to binding without the antibody) (see Example 6); and / or m) binds to the human HLA-G β2M MHC I complex (comprising SEQ ID NO:25) and inhibits binding of ILT2 to monomeric and / or dimeric and / or trimeric HLA-G β2M MHC I complexes by more than 60% (compared to binding without antibody) and inhibits binding of ILT4 to dimeric and / or trimeric HLA-G β2M MHC I complexes by more than 50% (compared to binding without antibody) (see e.g. Example 4b).

[0102] One embodiment of the invention is an isolated antibody that binds to human HLA-G, the antibody comprising: A) (a) a VH domain comprising (i) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1, (ii) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2, and (iii) an HVR-H3 comprising an amino acid sequence selected from SEQ ID NO: 3; and (b) a VL domain comprising (i) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (ii) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and (iii) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6; or B) (a) a VH domain comprising (i) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 9, (ii) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10, and (iii) an HVR-H3 comprising an amino acid sequence selected from SEQ ID NO: 11; and (b) a VL domain comprising (i) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12; (ii) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13, and (iii) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14. Including, The antibodies of A) or B) are independently characterized by the following properties: the anti-HLA-G antibody is a) binds to the human HLA-G β2M MHC I complex comprising SEQ ID NO: 25; and / or b) does not cross-react with (does not specifically bind to) a modified human HLA-G β2M MHC I complex comprising SEQ ID NO: 26; and / or c) does not cross-react with (does not specifically bind to) the human HLA-A2 β2M MHC I complex comprising SEQ ID NO:21 and SEQ ID NO:19; and / or d) does not cross-react with (does not specifically bind to) the mouse H2Kd β2M MHC I complex containing SEQ ID NO:27; and / or e) does not cross-react with (does not specifically bind to) the rat RT1A β2M MHC I complex containing SEQ ID NO:29; and / or f) inhibiting binding of ILT2 to a monomeric HLA-G β2M MHC I complex (comprising SEQ ID NO: 25); and / or g) inhibits binding of ILT2 to a monomeric HLA-G β2M MHC I complex (comprising SEQ ID NO: 25) by more than 50% (in one embodiment by more than 70%) (when compared to binding without the antibody); and / or h) inhibits the binding of ILT2 to monomeric and / or dimeric and / or trimeric HLA-G β2M MHC I complexes (comprising SEQ ID NO: 25) by more than 50% (in one embodiment by more than 70%) (when compared to binding without the antibody); and / or i) inhibits (by more than 50%, in one embodiment by more than 80%) the binding of ILT2 to HLA-G (ATCC No. HTB36) on JEG3 cells (when compared to binding without the antibody) (see Example 6); and / or j) binds to human HLA-G (ATCC No. HTB36) on JEG3 cells (see Example 5) and inhibits (by more than 50%, in one embodiment by more than 80%) the binding of ILT2 to HLA-G (ATCC No. HTB36) on JEG3 cells (when compared to binding without the antibody) (see Example 6); and / or k) binds to the human HLA-G β2M MHC I complex (comprising SEQ ID NO: 25) and inhibits binding of ILT2 to monomeric and / or dimeric and / or trimeric HLA-G β2M MHC I complexes by greater than 60% (compared to binding without antibody) and inhibits binding of ILT4 to dimeric and / or trimeric HLA-G β2M MHC I complexes by greater than 50% (compared to binding without antibody) (see e.g. Example 4b).

[0103] In one embodiment of the invention the antibody is of the IgG1 isotype. In one embodiment of the invention the antibody is of the IgG1 isotype comprising the mutations L234A, L235A and P329G (numbering according to EU index as per Kabat).

[0104] In further aspects, the anti-HLA-G antibody according to any of the above embodiments may incorporate any of the functions, either alone or in combination, as described in Sections 1-7 below.

[0105] 1. Antibody affinity In certain embodiments, the antibodies provided herein have a cytotoxicity of ≦1 μM, ≦100 nM, ≦10 nM, ≦1 nM, ≦0.1 nM, ≦0.01 nM, or ≦0.001 nM (e.g., 10 -8 M or less, e.g. 10 -8 M to 10 -13 M, for example 10 -9 M to 10 -13 It has a dissociation constant KD of 0.01 M.

[0106] In a preferred embodiment, KD is measured using a surface plasmon resonance assay using a BIACORE® with an antigen CM5 chip immobilized at ∼10 response units (RU) at 25°C. Briefly, a carboxymethylated dextran biosensor chip (CM5, BIACORE, Inc.) is activated with N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) according to the supplier's instructions. Antigen is diluted to 5 μg / ml (∼0.2 μM) in 10 mM sodium acetate (pH 4.8) and then injected at a flow rate of 5 μl / min to achieve approximately 10 response units (RU) of bound protein. After antigen injection, 1 M ethanolamine is injected to block unreacted groups. For kinetic measurements, two-fold serial dilutions of Fab (0.78 nM to 500 nM) were incubated at 25° C. and a flow rate of approximately 25 μl / min in 0.05% polysorbate 20 (TWEEN-20 TM ) in PBS containing surfactant (PBST). Association rates (k on or ka) and dissociation rate (k off Calculate the equilibrium dissociation constant (KD) as kd / ka (k off / k on) ratio. See, for example, Chen, Y. et al., J. Mol. Biol. 293(1999)865-881. When the association rate by the above surface plasmon resonance assay is 10 6 M -1 s -1 If the association rate exceeds 100%, the association rate can be measured using a spectrophotometer, e.g., a spectrophotometer equipped with a flow stop (Aviv Instruments) or an 8000 series SLM-AMINCO equipped with a stirred cuvette. TM It can be measured using a fluorescence quenching technique that measures the increase or decrease in fluorescence emission intensity (excitation = 295 nm; emission = 340 nm, band pass = 16 nm) of an anti-antigen antibody (Fab type) at 25°C and 20 nM in PBS (pH 7.2) in the presence of increasing concentrations of antigen measured with a spectrophotometer (ThermoSpectronic).

[0107] 2. Antibody fragment In certain embodiments, the antibodies provided herein are antibody fragments. Antibody fragments include, but are not limited to, Fab, Fab', Fab'-SH, F(ab')2, Fv, and scFv fragments, as well as other fragments described below. For a review of certain antibody fragments, see Hudson, PJ et al., Nat. Med. 9(2003)129-134. For a review of scFv fragments, see, e.g., The Pharmacology of Monoclonal Antibodies, Vol. 113, Rosenburg and Moore(eds.), Springer-Verlag, New York(1994), pp. 269-315; see also WO 93 / 16185; and U.S. Pat. Nos. 5,571,894 and 5,587,458. See US Pat. No. 5,869,046 for a discussion of Fab and F(ab')2 fragments that contain salvage receptor binding epitope residues and have increased in vivo half-lives.

[0108] Diabodies are antibody fragments with two antigen-binding sites that can be bivalent or bispecific. See, e.g., EP 0404097; WO 1993 / 01161; Hudson, PJ et al., Nat. Med. 9(2003)129-134; and Holliger, P. et al., Proc. Natl. Acad. Sci. USA 90(1993)6444-6448. Triabodies and tetrabodies are also described in Hudson, PJ et al., Nat. Med.9(20039 129-134).

[0109] A single domain antibody is an antibody fragment that contains all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody. In certain embodiments, a single domain antibody is a human single domain antibody (Domantis, Inc., Waltham, MA; see, e.g., U.S. Patent No. 6,248,516 B1).

[0110] Antibody fragments can be produced by a variety of techniques, including, but not limited to, proteolytic digestion of intact antibodies as well as production by recombinant host cells (e.g., E. coli or phages), as described herein.

[0111] 3. Chimeric and humanized antibodies In certain embodiments, the antibody provided herein is a chimeric antibody. Certain chimeric antibodies are described, for example, in U.S. Patent No. 4,816,567, and Morrison, SL et al., Proc. Natl. Acad. Sci. USA 81(1984)6851-6855). In one example, a chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a non-human primate, such as a mouse, rat, hamster, rabbit, or monkey) and a human constant region. In a further example, a chimeric antibody is a "class-switched" antibody whose class or subclass has been changed from that of the parent antibody. A chimeric antibody includes an antigen-binding fragment thereof.

[0112] In certain embodiments, a chimeric antibody is a humanized antibody. Typically, a non-human antibody has been humanized to reduce immunogenicity to humans while retaining the specificity and affinity of the parent non-human antibody. In general, a humanized antibody comprises one or more variable domains in which the HVRs (e.g., CDRs) (or portions thereof) are derived from a non-human antibody and the FRs (or portions thereof) are derived from human antibody sequences. The humanized antibody will also optionally comprise at least a portion of a human constant region. In some embodiments, some FR residues of the humanized antibody are replaced with the corresponding residues from the non-human antibody (e.g., the antibody from which the HVR residues are derived), e.g., to restore or improve antibody specificity or affinity.

[0113] Humanized antibodies and methods for their production are reviewed, for example, in Almagro, JC and Fransson, J., Front. Biosci. 13(2008)1619-1633 and further described, for example, in Riechmann, I. et al., Nature 332(1988)323-329; Queen, C. et al., Proc. Natl. Acad. Sci. USA 86(1989)10029-10033; U.S. Pat. Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmiri, SV et al., Methods 36(2005)25-34 (describing SDR(a-CDR) grafting); Padlan, EA, Mol. Immunol. 28(1991)489-498 (describing "resurfacing"); Dall'Acqua, WF et al., Methods 36(2005)43-60 (describing "FR shuffling"); and Osbourn, J. et al., Methods 36(2005)61-68 and Klimka, A. et al., Br. J. Cancer 83(2000)252-260 (describing a "guided selection" approach to FR shuffling).

[0114] Human framework regions that may be used for humanization include, but are not limited to, framework regions selected using the "best-fit" method (see, e.g., Sims, MJ et al., J. Immunol. 151(1993)2296-2308); framework regions derived from consensus sequences of human antibodies of a particular subgroup of light or heavy chain variable regions (see, e.g., Carter, P. et al., Proc. Natl. Acad. Sci. USA 89(1992)4285-4289; and Presta, LG et al., J. Immunol. 151(1993)2623-2632); human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro, JC and Fransson, J., Front. Biosci. 13(2008)1619-1633); and framework regions derived from FR library screening (see, e.g., Baca, M. et al., J. Biol. Chem. 272(1997)10678-10684 and Rosok, MJ et al., J. Biol. Chem. 271(19969 22611-22618).

[0115] 4. Human antibodies In certain embodiments, the antibody provided herein is a human antibody.Human antibodies can be produced using various techniques known in the art.Human antibodies are reviewed in van Dijk, MA and van de Winkel, JG, Curr. Opin. Pharmacol. 5(2001)368-374 and Lonberg, N., Curr. Opin. Immunol. 20(2008)450-459.

[0116] Human antibodies can be prepared by administering an immunogen to a transgenic animal that has been engineered to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge. Such animals typically contain all or part of a human immunoglobulin locus that replaces the endogenous immunoglobulin locus or is present extrachromosomally or randomly integrated into the animal's chromosomes. In such transgenic mice, the endogenous immunoglobulin locus is generally inactivated. For a review of methods for obtaining human antibodies from transgenic animals, see Lonberg, N., Nat. Biotech. 23(2005)1117-1125. See also, for example, XENOMOUSE. TM See also U.S. Patent Nos. 6,075,181 and 6,150,584, describing HuMab® technology, U.S. Patent No. 5,770,429, describing HuMab® technology, U.S. Patent No. 7,041,870, describing KM MOUSE® technology, and U.S. Patent Application Publication No. 2007 / 0061900, describing VelociMouse® technology. The human variable regions from intact antibodies produced by such animals can be further modified, for example, by combining with a different human constant region.

[0117] Human antibodies can also be produced by hybridoma-based methods. Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described. (See, for example, Kozbor, D., J. Immunol. 133(1984)3001-3005; Brodeur, BR et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York(1987), pp. 51-63; and Boerner, P. et al., J. Immunol. 147(1991)86-95). Human antibodies produced via human B-cell hybridoma technology are also described in Li, J. et al., Proc. Natl. Acad. Sci. USA 103(2006)3557-3562. Further methods include those described, for example, in U.S. Patent No. 7,189,826 (describing the production of monoclonal human IgM antibodies from hybridoma cell lines) and Ni, J., Xiandai Mianyixue 26 (2006) 265-268 (describing human-human hybridomas). Human hybridoma technology (trioma technology) is also described in Vollmers, HP and Brandlein, S., Histology and Histopathology 20 (2005) 927-937 and Vollmers, HP and Brandlein, S., Methods and Findings in Experimental and Clinical Pharmacology 27 (2005) 185-191.

[0118] Human antibodies can also be generated by isolating Fv clone variable domain sequences selected from a human-derived phage display library. Such variable domain sequences may then be combined with the desired human constant domains. Techniques for selecting human antibodies from antibody libraries are described below.

[0119] 5. Library-derived antibodies Antibodies of the invention can be isolated by screening combinatorial libraries for antibodies with one or more desired activities. For example, various methods are known in the art for generating phage display libraries and screening such libraries for antibodies with the desired binding characteristics. Such methods are reviewed, for example, in Hoogenboom, HR et al., Methods in Molecular Biology 178(2001)1-37 and further described, for example, in McCafferty, J. et al., Nature 348(1990)552-554; Clackson, T. et al., Nature 352(1991)624-628; Marks, JD et al., J. Mol. Biol. 222(1992)581-597; Marks, JD and Bradbury, A., Methods in Molecular Biology 248(2003)161-175; Sidhu, SS et al., J. Mol. Biol. 338(2004)299-310; Lee, CV et al., J. Mol. Biol. 340(2004)1073-1093; Fellouse, FA, Proc. Natl. Acad. Sci. USA 101(2004)12467-12472; and Lee, CV et al., J. Immunol. Methods 284(2004)119-132.

[0120] In a particular phage display method, repertoires of VH and VL genes can be cloned separately by polymerase chain reaction (PCR), randomly recombined into phage libraries, and then screened for antigen-binding phages, as described in Winter, G. et al., Ann. Rev. Immunol. 12(1994)433-455. Phages typically display antibody fragments as either single-chain Fv (scFv) fragments or Fab fragments. Libraries from immunized sources provide high affinity antibodies to immunogens without the need to construct hybridomas. Alternatively, naive repertoires can be cloned (e.g., from humans) to provide a single source of antibodies against a wide range of non-self and self antigens without any immunization, as described in Griffiths, AD et al., EMBO J. 12(1993)725-734. Finally, naive libraries can also be generated synthetically by cloning unrearranged V gene segments from stem cells and using PCR primers containing random sequences to encode the highly variable CDR3 regions and achieve in vitro rearrangement as described by Hoogenboom, HR and Winter, G., J. Mol. Biol. 227(1992)381-388. Patent publications describing human antibody phage libraries include, for example, U.S. Pat. No. 5,750,373, and U.S. Patent Application Publication Nos. 2005 / 0079574, 2005 / 0119455, 2005 / 0266000, 2007 / 0117126, 2007 / 0160598, 2007 / 0237764, 2007 / 0292936, and 2009 / 0002360.

[0121] Antibodies or antibody fragments isolated from a human antibody library are considered herein to be human antibodies or human antibody fragments.

[0122] 6. Multispecific antibodies In certain embodiments, the antibodies provided herein are multispecific antibodies, e.g., bispecific antibodies. Multispecific antibodies are monoclonal antibodies that have binding specificities for at least two different sites. In certain embodiments, one of the binding specificities is for HLA-G and the other is for any other antigen. In certain embodiments, bispecific antibodies can bind to two different epitopes of HLA-G. Bispecific antibodies can also be used to localize cytotoxic agents to cells expressing HLA-G. Bispecific antibodies can be prepared as full-length antibodies or antibody fragments.

[0123] Techniques for making multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy-light chain pairs with different specificities (see Milstein, C. and Cuello, A. C., Nature 305 (1983) 537-540; WO 93 / 08829; and Traunecker, A. et al., EMBO J. 10 (1991) 3655-3659) and "knob-in-hole" engineering (see, e.g., U.S. Pat. No. 5,731,168). Multispecific antibodies can also be produced by manipulating electrostatic steering effects to create antibody Fc-heterodimeric molecules (WO 2009 / 089004); cross-linking two or more antibodies or fragments (see, e.g., U.S. Pat. No. 4,676,980, and Brennan, M. et al., Science 229(1985)81-83); using leucine zippers to generate bispecific antibodies (see, e.g., Kostelny, SA et al., J. Immunol. 148(1992)1547-1553); using "diabody" technology to create bispecific antibody fragments (see, e.g., Holliger, P. et al., Proc. Natl. Acad. Sci. USA 90(1993)6444-6448); using single-chain Fv (sFv) dimers (see, e.g., Gruber, M et al., J. Immunol. 152(1994)5368-5374); and, for example, by preparing trispecific antibodies as described in Tutt, A. et al., J. Immunol. 147(1991)60-69.

[0124] Also included herein are engineered antibodies having three or more functional antigen binding sites, including "Octopus antibodies" (see, eg, US Patent Application Publication No. 2006 / 0025576).

[0125] The antibodies or fragments herein also include "Dual Acting Fabs" or "DAFs" which contain antigen binding sites that bind to HLA-G and another distinct antigen (see, e.g., U.S. Patent Application Publication No. 2008 / 0069820).

[0126] The antibodies or fragments herein may also be those described in WO 2009 / 080251, WO 2009 / 080252, WO 2009 / 080253, WO 2009 / 080254, WO 2010 / 112193, WO 2010 / 115589, WO 2010 / 136172, WO 2010 / 145792, and and the multispecific antibodies described in WO 2010 / 145793, WO 2011 / 117330, WO 2012 / 025525, WO 2012 / 025530, WO 2013 / 026835, WO 2013 / 026831, WO 2013 / 164325 or WO 2013 / 174873.

[0127] 7. Antibody Variants In certain embodiments, amino acid sequence variants of the antibodies provided herein are contemplated. For example, it may be desired to improve the binding affinity and / or other biological properties of the antibody. Amino acid sequence variants of the antibody can be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody or by peptide synthesis. Such modifications include, for example, deletions from, and / or insertions into, and / or substitutions of residues within the amino acid sequence of the antibody. Any combination of deletions, insertions, and substitutions can be made to arrive at the final construct, provided that the final construct possesses the desired properties, e.g., antigen binding.

[0128] Substitution, insertion, and deletion mutants In certain embodiments, antibody variants are provided that have one or more amino acid substitutions. Sites of interest for substitution mutations include HVRs and FRs. Exemplary changes are shown in Table 1 under the heading of "Exemplary Substitutions" and are further described below with reference to classes of amino acid side chains. Conservative substitutions are shown in Table 1 under the heading of "Preferred Substitutions." Amino acid substitutions can be introduced into an antibody of interest and the products screened for the desired activity, e.g., retained / improved antigen binding, reduced immunogenicity, or improved ADCC or CDC.

[0129] TIFF0007592050000002.tif183170

[0130] Amino acids can be grouped according to common side chain properties: (1) Hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile; (2) Neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) Acidic: Asp, Glu; (4) Basic: His, Lys, Arg; (5) Residues that affect chain orientation: Gly, Pro; (6) Aromatic: Trp, Tyr, Phe

[0131] Non-conservative substitutions will entail exchanging a member of one of these classes for another class.

[0132] One type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g., a humanized or human antibody). Typically, the resulting variants selected for further study will have modified (e.g., improved) certain biological properties (e.g., improved affinity, reduced immunogenicity) compared to the parent antibody and / or will substantially retain certain biological properties of the parent antibody. An exemplary substitutional variant is an affinity matured antibody, which is conveniently generated, for example, using phage display-based affinity maturation techniques as described herein. Briefly, one or more HVR residues are mutated and the variant antibodies are displayed on phage and screened for a particular biological activity (e.g., binding affinity).

[0133] Alterations (e.g., substitutions) can be made in the HVRs, for example to improve the affinity of the antibody. Such alterations can be made in "hot spots" of the HVRs, i.e., residues encoded by codons that undergo frequent mutation during the somatic maturation process (see, e.g., Chowdhury, PS, Methods Mol. Biol. 207(2008)179-196), and / or in the SDRs (a-CDRs), and the resulting variant VH or VL are tested for binding affinity. Affinity maturation by construction and reselection from secondary libraries is described, for example, in Hoogenboom, HR et al. in Methods in Molecular Biology 178(2002)1-37. In some embodiments of affinity maturation, diversity is introduced into the variable genes selected for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis). A secondary library is then created. This library is then screened to identify any antibody variants with the desired affinity. Another method of introducing diversity involves an HVR-directed approach in which multiple HVR residues (e.g., 4 to 6 residues at a time) are randomized. HVR residues involved in antigen binding can be specifically identified, for example, using alanine scanning mutagenesis, or modeling. In particular, CDR-H3 and CDR-L3 are often targeted.

[0134] In certain embodiments, substitutions, insertions or deletions may be made within one or more HVRs, so long as these modifications do not substantially reduce the ability of the antibody to bind to the antigen. For example, conservative changes (e.g., conservative substitutions as provided herein) that do not substantially reduce binding affinity may be made within an HVR. Such changes may be outside of HVR "hot spots" or SDRs. In certain embodiments of the variant VH or VL sequences provided above, each HVR is unchanged or contains at most one, two or three amino acid substitutions.

[0135] A useful method for identifying antibody residues or regions that can be targeted for mutagenesis is called "alanine scanning mutagenesis" as described by Cunningham, BC and Wells, JA, Science 244 (1989) 1081-1085. In this method, target residues or groups (e.g., charged residues such as arg, asp, his, lys, and glu) are identified and substituted with neutral or negatively charged amino acids (e.g., alanine or polyalanine) to determine whether antigen-antibody interactions are affected. Further substitutions can be introduced at amino acid positions that show functional sensitivity to the initial substitution. Alternatively or additionally, a crystal structure of an antigen-antibody complex to identify antibody-antigen contact points. Such contact and adjacent residues can be targeted as candidates for substitution or can be eliminated. The mutants are screened to determine whether they contain the desired properties.

[0136] Amino acid sequence insertions include amino- and / or carboxyl terminal fusions ranging in length from one residue to polypeptides having a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. An example of a terminal insertion includes an antibody with an N-terminal methionine residue. Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme (e.g., for ADEPT) or a polypeptide which extends the serum half-life of the antibody.

[0137] b) Fc region mutants In certain embodiments, one or more amino acid modifications can be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant. The Fc region variant can comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3, or IgG4 Fc region) containing an amino acid modification (e.g., a substitution) at one or more amino acid positions.

[0138] Antibodies with reduced effector function include those containing substitutions at one or more of Fc region residues 238, 265, 269, 270, 297, 327 and 329 (U.S. Patent No. 6,737,056). Such Fc variants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, including so-called "DANA" Fc mutants with substitutions of residues 265 and 297 to alanine (U.S. Patent No. 7,332,581).

[0139] Certain antibody variants with improved or diminished binding to FcRs have been described (see, e.g., U.S. Pat. No. 6,737,056; WO 2004 / 056312; and Shields, RL et al., J. Biol. Chem. 276(2001)6591-6604).

[0140] In one embodiment of the invention, such an antibody is an IgG1 comprising the mutations L234A and L235A, or the mutations L234A, L235A and P329G. In another embodiment, such an antibody is an IgG4 comprising the mutations S228P and L235E, or S228P, L235E or / and P329G (numbering according to the EU index in Kabat et al, Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991).

[0141] Antibodies with extended half-life and improved binding to the neonatal Fc receptor (FcRn), which is responsible for the transfer of maternal IgG to the fetus (Guyer, RL et al., J. Immunol. 117(1976)587-593, and Kim, JK et al., J. Immunol. 24(1994)2429-2434), have been described in U.S. Patent Application Publication No. 2005 / 0014934. These antibodies comprise an Fc region with one or more substitutions which improve binding of the Fc region to FcRn. Such Fc variants include those which contain a substitution at one or more of the following Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, ​​413, 424 or 434, e.g., a substitution at Fc region residue 434 (U.S. Patent No. 7,371,826).

[0142] See also Duncan, AR and Winter, G., Nature 322 (1988) 738-740; U.S. Patent Nos. 5,648,260; 5,624,821; and WO 94 / 29351 for other examples of Fc region variants.

[0143] c) Cysteine ​​Engineered Antibody Variants In certain embodiments, it is desirable to generate cysteine ​​engineered antibodies, e.g., "ThioMabs," in which one or more residues of an antibody are replaced with a cysteine ​​residue. In certain embodiments, the replaced residues occur at accessible sites of the antibody. By replacing those residues with cysteine, reactive thiol groups are thereby placed at accessible sites of the antibody, which can be used to conjugate the antibody to other moieties, such as, for example, drug moieties or linker-drug moieties, to generate immunoconjugates, as further described herein. In certain embodiments, any one or more of the following residues are replaced with cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; and S400 (EU numbering) of the heavy chain Fc region. Cysteine ​​engineered antibodies can be generated, for example, as described in U.S. Pat. No. 7,521,541.

[0144] d) Antibody derivative In certain embodiments, the antibodies provided herein can be further modified to include additional non-protein moieties that are known in the art and readily available. Moieties suitable for derivatization of antibodies include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol / propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymers, polyamino acids (either homopolymers or random copolymers) and dextran or poly(n-vinylpyrrolidone) polyethylene glycol, propylene glycol homopolymer, prolypropylene oxide / ethylene oxide copolymer, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have manufacturing advantages due to its stability in water. The polymer may be of any molecular weight and may be branched or unbranched. The number of polymers attached to an antibody can vary, and when more than one polymer is attached, they can be the same or different molecules. Generally, the number and / or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular property or function of the antibody to be improved and whether the antibody derivative will be used in therapy under defined conditions.

[0145] In another embodiment, a conjugate of an antibody and a non-protein moiety is provided that can be selectively heated by exposure to radiation. In one embodiment, the non-protein moiety is a carbon nanotube (Kam, NW et al., Proc. Natl. Acad. Sci. USA 102(2005)11600-11605). The radiation can be of any wavelength, including but not limited to wavelengths that heat the non-protein moiety to a temperature that is not harmful to normal cells but kills cells proximal to the antibody-non-protein moiety.

[0146] B. Recombinant Methods and Compositions Antibodies can be produced using recombinant methods and compositions, e.g., as described in U.S. Pat. No. 4,816,567. In one embodiment, an isolated nucleic acid is provided encoding an anti-HLA-G antibody described herein. Such a nucleic acid can encode an amino acid sequence comprising the VL of the antibody, and / or an amino acid sequence comprising the VH of the antibody (e.g., the light and / or heavy chains of the antibody). In a further embodiment, one or more vectors (e.g., expression vectors) comprising such a nucleic acid are provided. In a further embodiment, a host cell comprising such a nucleic acid is provided. In one embodiment, the host cell comprises (e.g., is transformed with) (1) a vector comprising a nucleic acid encoding an amino acid sequence comprising the VL of the antibody and an amino acid sequence comprising the VH of the antibody, or (2) a first vector comprising a nucleic acid encoding an amino acid sequence comprising the VL of the antibody and a second vector comprising a nucleic acid encoding an amino acid sequence comprising the VH of the antibody. In one embodiment, the host cell is a eukaryotic cell, e.g., a Chinese Hamster Ovary (CHO) cell, a HEK293 cell, or a lymphoid cell (e.g., a Y0, NS0, Sp20 cell). In one embodiment, a method for producing an anti-HLA-G antibody is provided, comprising culturing a host cell comprising nucleic acid encoding the antibody under conditions suitable for expression of the antibody, as described above, and optionally recovering the antibody from the host cell (or host cell medium).

[0147] For recombinant production of an anti-HLA-G antibody, nucleic acid encoding the antibody, e.g., as described above, is isolated and inserted into one or more vectors for further cloning and / or expression in a host cell. Such nucleic acid can be readily isolated and sequenced using standard procedures (e.g., by using oligonucleotide probes capable of binding specifically to genes encoding the heavy and light chains of the antibody).

[0148] Suitable host cells for cloning or expressing antibody-encoding vectors include prokaryotic or eukaryotic cells as described herein. For example, antibodies can be produced in bacteria, particularly if glycosylation and Fc effector functions are not required. For expression of antibody fragments and polypeptides in bacteria, see, for example, U.S. Pat. Nos. 5,648,237, 789,199, and 5,840,523 (see also Charlton, KA, In: Methods in Molecular Biology, Vol. 248, Lo, BKC(ed.), Humana Press, Totowa, NJ(2003), pp. 245-254, which describes the expression of antibody fragments in E. coli). After expression, the antibody can be isolated from the bacterial cell paste in a soluble fraction and further purified.

[0149] In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungal and yeast strains in which the glycosylation pathway has been "humanized," resulting in the production of antibodies with partial or fully human glycosylation patterns. See Gerngross, TU, Nat. Biotech. 22(2004)1409-1414; and Li, H. et al., Nat. Biotech. 24(2006)210-215.

[0150] Suitable host cells for the expression of glycosylated antibodies can also be obtained from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant cells and insect cells. Numerous baculovirus strains have been identified that can be used in conjunction with insect cells, particularly for the transfection of Spodoptera frugiperda cells.

[0151] Plant cell cultures can also be used as hosts. See, for example, U.S. Patent Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (PLANTIBODIES FOR ANTIBODY PRODUCTION IN TRANSGENIC PLANTS).TM See description of technology.

[0152] Vertebrate cells can also be used as hosts. For example, mammalian cell lines adapted to grow in suspension can be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed with SV40 (COS-7); human embryonic kidney lines (e.g., 293 cells or 293 cells described in Graham, FL et al., J. Gen Virol. 36(1977)59-74); baby hamster kidney cells (BHK); mouse Sertoli cells (e.g., TM4 cells described in Mather, JP, Biol. Reprod. 23(1980)243-252); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK); buffalo rat liver cells (BRL 3A); human lung cells (W138); human hepatocytes (HepG2); mouse mammary tumor cells (MMT060562); e.g., Mather, JP et al., Annals NY Acad. Sci. 383 (1982) 44-68; MRC5 cells; and FS4 cells. Other useful mammalian host cell lines are DHFR cells, - Chinese hamster ovary (CHO) cells, including CHO cells (Urlaub, G. et al., Proc. Natl. Acad. Sci. USA 77(1980)4216-4220); and myeloma cell lines such as Y0, NS0 and Sp2 / 0. For a review of certain mammalian host cell lines suitable for antibody production, see, e.g., Yazaki, P. and Wu, AM, Methods in Molecular Biology, Vol. 248, Lo, BKC(ed.), Humana Press, Totowa, NJ(2004), pp. 255-268.

[0153] C. Assay The anti-HLA-G antibodies provided herein may be identified and screened or characterized for their physical / chemical properties and / or biological activity by various assays known in the art.

[0154] 1. Binding Assays and Other Assays In one embodiment, the antibodies of the invention are tested for their antigen binding activity by known methods, such as, for example, ELISA, Western blot, etc.

[0155] In another aspect, a competitive assay can be used to identify antibodies that compete with HLA-G-0032 (comprising the VH sequence of SEQ ID NO: 7 and the VL sequence of SEQ ID NO: 8) for binding to HLA-G. One embodiment of the present invention is an antibody that competes with an anti-HLA-G antibody that comprises all three HVRs of the VH sequence of SEQ ID NO: 7 and all three HVRs of the VL sequence of SEQ ID NO: 8 for binding to human HLA-G. In a particular embodiment, such a competing antibody binds to the same epitope (e.g., a linear or conformational epitope) bound by the anti-HLA-G antibody HLA-G-0032. In one embodiment, an anti-HLA-G antibody is provided that binds to the same epitope on HLA-G as an antibody that comprises the VH sequence of SEQ ID NO: 7 and the VL sequence of SEQ ID NO: 8. In another aspect, a competitive assay can be used to identify antibodies that compete with HLA-G-0037 (comprising the VH sequence of SEQ ID NO: 15 and the VL sequence of SEQ ID NO: 16) for binding to HLA-G. One embodiment of the present invention is an antibody that competes with an anti-HLA-G antibody comprising all three HVRs of the VH sequence of SEQ ID NO: 15 and all three HVRs of the VL sequence of SEQ ID NO: 16 for binding to human HLA-G. In a particular embodiment, such a competing antibody binds to the same epitope (e.g., a linear or conformational epitope) bound by the anti-HLA-G antibody HLA-G-0037. In one embodiment, an anti-HLA-G antibody is provided that binds to the same epitope on HLA-G as an antibody comprising the VH sequence of SEQ ID NO: 15 and the VL sequence of SEQ ID NO: 16. Details of an exemplary method for mapping the epitope to which an antibody binds are provided in Morris, GE (ed.), Epitope Mapping Protocols, In: Methods in Molecular Biology, Vol. 66, Humana Press, Totowa, NJ (1996).

[0156] In an exemplary competitive assay, immobilized HLA-G is incubated in a solution containing a first labeled antibody that binds to HLA-G (e.g., anti-HLA-G antibodies HLA-G-0032 or HLA-G.0037) and a second unlabeled antibody that is being tested for its ability to compete with the first antibody for binding to HLA-G. The second antibody can be present in the hybridoma supernatant. As a control, immobilized HLA-G is incubated in a solution containing the first labeled antibody but not the second unlabeled antibody. After incubation under conditions that allow binding of the first antibody to HLA-G, excess unbound antibody is removed and the amount of label bound to the immobilized HLA-G is measured. If the amount of label bound to the immobilized HLA-G is substantially reduced in the test sample compared to the control sample, it indicates that the second antibody competes with the first antibody for binding to HLA-G. See Harlow, E. and Lane, D., Antibodies: A Laboratory Manual, Chapter 14, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1988). For another exemplary competition assay, see Example 2 (epitope mapping ELISA / binding competition assay).

[0157] 2. Activity Assay In one embodiment, an assay is provided to identify anti-HLA-G antibodies that have biological activity. Biological activity can include, for example, the ability to enhance activation and / or proliferation of various immune cells, including T cells. For example, it enhances the secretion of immunomodulatory cytokines, such as interferon gamma (IFN-gamma) and / or tumor necrosis factor alpha (TNFalpha). Other immunomodulatory cytokines that are or can be enhanced include, for example, IL1β, IL6, IL12, granzyme B, etc., which bind to various cell types. Also provided are antibodies that have such biological activity in vivo and / or in vitro.

[0158] In certain embodiments, antibodies of the invention are tested for biological activity, such as those described in the Examples below.

[0159] D. Immunoconjugates (cancer only or modified for targeting) The present invention also provides immunoconjugates comprising the anti-HLA-G antibodies herein conjugated to one or more cytotoxic agents, such as a chemotherapeutic agent or drug, a growth inhibitory agent, a toxin (e.g., a protein toxin, an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or a fragment thereof), or a radioactive isotope.

[0160] In one embodiment, the immunoconjugate is an antibody that is capable of binding to a compound selected from the group consisting of maytansinoids (see U.S. Pat. Nos. 5,208,020, 5,416,064, and EP Patent No. 0,425,235); auristatins, e.g., monomethylauristatin drug moieties DE and DF (MMAE and MMAF) (see U.S. Pat. Nos. 5,635,483, 5,780,588, and 7,498,298); dolastatins; calicheamicin or a derivative thereof (see U.S. Pat. Nos. 5,712,374, 714,586, 5,739,116, 5,767,285, 770701, 5,770710, 5,773,001, and 5,877,296; Hinman, LM et al., Cancer Res. 53(1993)3336-3342; and Lode, HN et al., Cancer Res. 58(1998)2925-2928); anthracyclines such as daunomycin or doxorubicin (Kratz, F. et al., Curr. Med. Chem. 13(2006)477-523; Jeffrey, SC et al., Bioorg. Med. Chem. Lett. 16(2006)358-362; Torgov, MY et al., Bioconjug. Chem. 16(2005)717-721; Nagy, A. et al., Proc. Natl. Acad. Sci. USA 97(2000)829-834; Dubowchik, GM et al., Bioorg. & Med. Chem. Letters 12(2002)1529-1532; King, HD et al., J. Med. Chem. 45 (20029 4336-4343; and U.S. Pat. No. 6,630,579); methotrexate; vindesine; taxanes, such as docetaxel, paclitaxel, larotaxel, tesetaxel, and ortataxel; trichothecenes; and antibody-drug conjugates (ADCs) conjugated to one or more drugs, including, but not limited to, CC1065.

[0161] In other embodiments, the immunoconjugate comprises an antibody as described herein conjugated to an enzymatically active toxin or fragment thereof, including, but not limited to, diphtheria A chain, nonbinding active fragment of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Abrasiongum protein, dianthin protein, Phytolacca lacryma protein (PAPI, PAPII, and PAP-S), bitter melon inhibitor, curcin, crotin, saponaria inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the trichothecenes.

[0162] In other embodiments, the immunoconjugate comprises an antibody as described herein conjugated to a radioactive atom to form a radioconjugate. A variety of radioisotopes are available for the production of radioconjugates. Examples include At 211 , I 131 , I 125 , Y 90 , Re 186 , Re 188 , Sm 153 , Bi 212 , P 32 , Pb 212 Radioactive conjugates, when used for detection, include radioactive atoms for scintigraphic examinations, e.g., TC 99m Or I 123 , or spin labels for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, MRI), such as iodine-123 again, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron.

[0163] Conjugates of antibodies and cytotoxic agents can be made using a variety of bifunctional protein coupling agents, such as N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters (e.g., dimethyl adipimidate HCl), active esters (e.g., disuccinimidyl suberate), aldehydes (e.g., glutaraldehyde), bisazide compounds (e.g., bis(p-azidobenzoyl)hexanediamine), bis-diazonium derivatives (e.g., bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (e.g., toluene 2,6-diisocyanate), and diactive fluorine compounds (e.g., 1,5-difluoro-2,4-dinitrobenzene). For example, ricin immunotoxins can be prepared as described in Vitetta, ES et al., Science 238(1987)1098-1104. Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylenetriaminepentaacetic acid (MX-DTPA) is an example of a chelating agent for conjugation of radionucleotides to antibodies. See WO 94 / 11026. The linker may be a "cleavable linker" that facilitates the release of the cytotoxic drug inside the cell. For example, acid-labile linkers, peptidase-sensitive linkers, photolabile linkers, dimethyl linkers or disulfide-containing linkers (Chari, RV et al., Cancer Res. 52(1992)127-131; U.S. Pat. No. 5,208,020) may be used.

[0164] Particularly contemplated are immunoconjugates or ADCs described herein that are prepared using cross-linking reagents such as, but not limited to, BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, sulfo-SMPB, and SVSB (succinimidyl-(4-vinylsulfone)benzoate), which are commercially available (e.g., from Pierce Biotechnology, Inc., Rockford, Ill., USA).

[0165] E. Methods and Compositions for Diagnostics and Detection In certain embodiments, any of the anti-HLA-G antibodies provided herein are useful for detecting the presence of HLA-G in a biological sample. As used herein, the term "detection" includes quantitative or qualitative detection. In certain embodiments, the biological sample comprises cells or tissues, such as immune or T cell infiltrates and / or tumor cells.

[0166] In one embodiment, an anti-HLA-G antibody is provided for use in a diagnostic or detection method. In a further aspect, a method for detecting the presence of HLA-G in a biological sample is provided. In a particular embodiment, the method comprises contacting a biological sample with an anti-HLA-G antibody as described herein under conditions that allow binding of the anti-HLA-G antibody to HLA-G, and detecting whether a complex is formed between the anti-HLA-G antibody and HLA-G. Such a method can be an in vitro or in vivo method. In one embodiment, the anti-HLA-G antibody is used to select subjects suitable for therapy with an anti-HLA-G antibody, e.g., HLA-G is a biomarker for patient selection.

[0167] In certain embodiments, labeled anti-HLA-G antibodies are provided. Labels include, but are not limited to, labels or moieties that are directly detected (e.g., fluorescent labels, chromophore labels, electron-dense labels, chemiluminescent labels, radioactive labels, etc.) as well as moieties such as enzymes or ligands that are indirectly detected, e.g., via enzymatic reactions or molecular interactions. Examples of such labels include, but are not limited to, radioisotopes. 32 P, 14 C. 125 I, 3 H, and 131 I, fluorophores such as rare earth chelates or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, luciferases such as firefly luciferase and bacterial luciferase (U.S. Pat. No. 4,737,456), luciferin, 2,3-dihydrophthalidinedione, horseradish peroxidase (HRP), alkaline phosphatase, β-galactosidase, glucoamylase, lysozyme, sugar oxidases such as glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase, heterocyclic oxidases such as uricase and xanthine oxidase coupled to enzymes that utilize hydrogen peroxide to oxidize dye precursors such as HRP, lactoperoxidase, or microperoxidase, biotin / avidin, spin labels, bacteriophage labels, stable free radicals, etc.

[0168] F. Pharmaceutical Formulations Pharmaceutical formulations of the anti-HLA-G antibodies described herein are prepared by mixing such antibodies having a desired degree of purity with one or more optional pharma- ceutically acceptable carriers (Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed.) (1980)) in the form of a lyophilized formulation or an aqueous solution. Typically, pharma- ceutically acceptable carriers are non-toxic to recipients at the dosages and concentrations employed, and include, but are not limited to, buffers such as phosphates, citrates, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (e.g., octadecyldimethylbenzylammonium chloride, hexamethonium chloride, benzalkonium chloride, benzethonium chloride, phenol, butyl or benzyl alcohol, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, 3-pentanol, and m-cresol); small molecule antibacterials such as glycerol, ... The present invention also includes a polypeptide of a small amount (less than about 10 residues); a protein such as serum albumin, gelatin or immunoglobulin; a hydrophilic polymer such as polyvinylpyrrolidone; an amino acid such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates including glucose, mannose or dextrin; a chelating agent such as EDTA; a sugar such as sucrose, mannitol, trehalose or sorbitol; a salt-forming counterion such as sodium; a metal complex (e.g., Zn-protein complex); and / or a non-ionic surfactant such as polyethylene glycol (PEG). Exemplary pharmacologic carriers herein further include an intercalating drug dispersing agent such as a soluble neutral active hyaluronidase glycoprotein (sHASEGP), e.g., a human soluble PH-20 hyaluronidase glycoprotein such as rhuPH20 (HYLENEX®, Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use, including rhuPH20, are described in U.S. Patent Application Publication Nos. 2005 / 0260186 and 2006 / 0104968.In one embodiment, the sHASEGP is combined with one or more additional glycosaminoglycanases, such as chondroitinases.

[0169] Exemplary lyophilized antibody formulations are described in U.S. Patent No. 6,267,958. Aqueous antibody formulations include those described in U.S. Patent No. 6,171,586 and WO 2006 / 044908, the latter formulations including a histidine-acetate buffer.

[0170] The formulations herein may also contain more than one active ingredient as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. For example, it may be desirable to provide more. Such active ingredients are suitably present in combination in amounts that are effective for the intended purpose.

[0171] The active ingredient can be entrapped in microcapsules, such as hydroxymethylcellulose microcapsules or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively, prepared by coacervation techniques or interfacial polymerization methods, in colloidal drug delivery systems (such as liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules), or in macroemulsions. These techniques are disclosed in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed.) (1980).

[0172] Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules.

[0173] Formulations to be used for in vivo administration must generally be sterile, and sterility is readily accomplished, for example, by filtration through sterile filtration membranes.

[0174] G. Treatment Methods and Compositions Any of the anti-HLA-G antibodies (or antigen binding proteins) provided herein can be used in therapeutic methods.

[0175] In one aspect, an anti-HLA-G antibody is provided for use as a medicine. In a further aspect, an anti-HLA-G antibody or use in the treatment of cancer is provided. In a particular embodiment, an anti-HLA-G antibody is provided for use in a method of treatment. In a particular embodiment, the invention provides an anti-HLA-G antibody for use in a method of treatment of an individual with cancer, the method comprising administering to such individual an effective amount of an anti-HLA-G antibody.

[0176] In a further embodiment, the invention provides an anti-HLA-G antibody for use as an immunomodulator / for use in directly or indirectly inducing proliferation, activation, e.g. by secretion of immunostimulatory cytokines such as TNF alpha (TNFa) and IFN gamma (IFNg) or further recruitment of immune cells. In a particular embodiment, the invention provides an anti-HLA-G antibody for use in an immunomodulator / for directly or indirectly inducing proliferation, activation, e.g. by secretion of immunostimulatory cytokines such as TNFa and IFN gamma or further recruitment of immune cells in an individual, comprising administering to the individual an effective amount of an anti-HLA-G antibody for immunomodulation / or for directly or indirectly inducing proliferation, activation, e.g. by secretion of immunostimulatory cytokines such as TNFa and IFN gamma or further recruitment of immune cells.

[0177] In a further embodiment, the invention provides anti-HLA-G antibodies for use as immunostimulatory agents and / or for stimulating tumor necrosis factor alpha (TNFalpha) secretion. In a particular embodiment, the invention provides anti-HLA-G antibodies for use in an immunomodulatory method for directly or indirectly inducing proliferation, activation, e.g. by secretion of immunostimulatory cytokines such as TNFa and IFNg or by further recruitment of immune cells, in an individual, comprising administering to the individual an effective amount of an anti-HLA-G antibody immunomodulatory for directly or indirectly inducing proliferation, activation, e.g. by secretion of immunostimulatory cytokines such as TNFa and IFNg or by further recruitment of immune cells.

[0178] The "individual" according to any of the above embodiments is preferably a human. In a further embodiment, the present invention provides the use of an anti-HLA-G antibody in the manufacture or preparation of a medicament. In one embodiment, the medicament is for the treatment of cancer. In a further embodiment, the medicament is for use in a method for the treatment of cancer, comprising administering to an individual having cancer an effective amount of the medicament. In a further embodiment, the medicament is for inducing cell-mediated lysis of cancer cells. In a further embodiment, the medicament is for use in a method for inducing cell-mediated lysis of cancer cells in an individual suffering from cancer, comprising administering to said individual an effective amount of the medicament to induce apoptosis in the cancer cells / or inhibit the proliferation of the cancer cells. The "individual" according to any of the above embodiments may be a human.

[0179] In a further aspect, the present invention provides a method for treating cancer. In one embodiment, the method comprises administering to an individual having cancer an effective amount of anti-HLA-G. The "individual" in any of the above embodiments may be a human.

[0180] In a further aspect, the present invention provides a method for inducing cell-mediated lysis of cancer cells in an individual suffering from cancer. In one embodiment, the method comprises administering to the individual suffering from cancer an effective amount of anti-HLA-G to induce cell-mediated lysis of cancer cells in said individual. In one embodiment, the "individual" is a human.

[0181] In a further aspect, the invention provides a pharmaceutical formulation comprising any of the anti-HLA-G antibodies provided herein, e.g., for use in any of the above-mentioned methods of treatment. In one embodiment, the pharmaceutical formulation comprises any of the anti-HLA-G antibodies provided herein and a pharma- ceutically acceptable carrier.

[0182] The antibodies (and any additional therapeutic agents) of the present invention can be administered by any suitable means, including parenterally, intrapulmonary, and intranasally, and may also be administered intralesionally if localized treatment is desired. Parenteral infusion includes intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. Dosing can be by any suitable route, for example, injection, such as intravenous or subcutaneous injection, depending in part on whether the administration is brief or chronic. Various dosing schedules are contemplated herein, including, but not limited to, single or multiple doses, bolus doses, and pulse infusions over various time points.

[0183] The antibodies of the invention are formulated, dosed, and administered in a manner consistent with good medical practice. Factors to be considered in this regard include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of drug delivery, the method of administration, the schedule of administration, and other factors known to medical practitioners. The antibodies of the invention are optionally, but not necessarily, formulated with one or more agents currently used to prevent or treat the disease in question. The effective amount of such other agents will depend on the amount of antibody present in the formulation, the type of disease or treatment, and other factors not mentioned above. These will generally be used in the same dosages and routes of administration as described herein, or at 1% to 99% of the doses described herein, or at any dosage and by any route determined to be empirically / clinically appropriate.

[0184] The dosage of the antibody of the invention suitable for preventing or treating a disease will depend on the type of disease being treated (when used alone or in combination with one or more additional therapeutic agents), the type of antibody, the severity and course of the disease, whether the antibody is administered for prophylactic or therapeutic purposes, previous treatments, the patient's medical history and response to the antibody, and the discretion of the attending physician. The antibody of the invention is suitably administered to the patient in a single dose or over a series of treatments. Depending on the type and severity of the disease, about 1 μg / kg to 15 mg / kg (e.g., 0.5 mg / kg to 10 mg / kg) of the antibody or immunoconjugate can be an initial candidate dose for administration to the patient, whether by one or more individual administrations or by continuous infusion. One typical daily dose ranges from about 1 μg / kg to 100 mg / kg or more, depending on the factors mentioned above. In the case of repeated administration over several days or more, depending on the condition, treatment will be sustained until a desired suppression of disease symptoms occurs. One exemplary dosage of the antibody would be about 0.05 mg / kg to about 10 mg / kg. Thus, one or more doses of about 0.5 mg / kg, 2.0 mg / kg, 4.0 mg / kg or 10 mg / kg (or any combination thereof) may be administered to the patient. Such doses may be administered intermittently, for example every week or every three weeks (e.g., such that the patient receives from about 2 to about 20, e.g., about 6 doses of the antibody). An initial high loading dose may be followed by one or more lower doses. An exemplary dosing regimen includes an initial loading dose of about 4 mg / kg, followed by weekly maintenance doses of about 2 mg / kg of the antibody. However, other dosing regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.

[0185] Any of the above formulations or methods of treatment can be carried out using an immunoconjugate of the invention in place of or in addition to an anti-HLA-G antibody.

[0186] Any of the above formulations or methods of treatment can be carried out using an immunoconjugate of the invention in place of or in addition to an anti-HLA-G antibody.

[0187] II. Manufactured products In another aspect of the invention, an article of manufacture is provided that includes materials useful for the treatment, prevention, and / or diagnosis of the disorders described above. The article of manufacture includes a container and a label or package insert on or associated with the container. Suitable containers include, by way of example, bottles, vials, syringes, IV infusion bags, and the like. The containers can be formed from a variety of materials, such as glass or plastic. The containers can hold a compound, alone or in combination with other compositions, that is effective in treating, preventing, and / or diagnosing a condition, and can have a sterile access port (e.g., the container can be an intravenous solution bag or vial with a stopper pierceable by a hypodermic needle). At least one active agent in the composition is an antibody of the invention. The label or package insert indicates that the composition is used for treating a selected condition. Additionally, the article of manufacture can include (a) a first container having therein a composition comprising an antibody of the invention, and (b) a second container having therein a composition comprising an additional cytotoxic or other therapeutic agent. The article of manufacture in this embodiment of the invention can further include a package insert indicating that the composition can be used to treat a particular condition. Alternatively, or additionally, the article of manufacture may further comprise a second (or third) container containing a pharma- ceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, and dextrose solution. The article of manufacture may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

[0188] The following examples and figures are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. Modifications can be made in the procedures set forth without departing from the spirit of the invention.

[0189] Explanation of amino acid sequence SEQ ID NO: 1 Heavy chain HVR-H1, HLA-G-0032 SEQ ID NO:2 Heavy chain HVR-H2, HLA-G-0032 SEQ ID NO: 3 Heavy chain HVR-H3, HLA-G-0032 SEQ ID NO: 4 Light chain HVR-L1, HLA-G-0032 SEQ ID NO:5 Light chain HVR-L2, HLA-G-0032 SEQ ID NO: 6 Light chain HVR-L3, HLA-G-0032 SEQ ID NO: 7 Heavy chain variable domain VH, HLA-G-0032 SEQ ID NO:8 Light chain variable domain VL, HLA-G-0032 SEQ ID NO: 9 Heavy chain HVR-H1, HLA-G-0037 SEQ ID NO: 10 Heavy chain HVR-H2, HLA-G-0037 SEQ ID NO: 11 Heavy chain HVR-H3, HLA-G-0037 SEQ ID NO: 12 Light chain HVR-L1, HLA-G-0037 SEQ ID NO: 13 Light chain HVR-L2, HLA-G-0037 SEQ ID NO: 14 Light chain HVR-L3, HLA-G-0037 SEQ ID NO: 15 Heavy chain variable domain VH, HLA-G-0037 SEQ ID NO: 16 Light chain variable domain VL, HLA-G-0037 SEQ ID NO: 17: Exemplary human HLA-G SEQ ID NO: 18: Exemplary human HLA-G extracellular domain (ECD) SEQ ID NO: 19: Exemplary human β2M SEQ ID NO: 20: Modified human HLA-G (ECD of HLA-G in which HLA-G specific amino acids have been replaced by HLA-A consensus amino acids (=degrafted HLA-G, see also FIG. 1) SEQ ID NO: 21: Exemplary human HLA-A2 SEQ ID NO: 22: Exemplary human HLA-A2 ECD SEQ ID NO: 23: Exemplary ECD of mouse H2Kd SEQ ID NO: 24: Exemplary rat RT1A ECD SEQ ID NO: 25: Exemplary human HLA-G β2M MHC class I complex SEQ ID NO: 26: Exemplary modified human HLA-G β2M MHC class I complex (HLA-G specific amino acids replaced by HLA-A consensus amino acids (=degrafted HLA-G) see also FIG. 1) SEQ ID NO: 27: Exemplary mouse H2Kd β2M MHC class I complex SEQ ID NO: 28: Exemplary human HLA-G / mouse H2Kd β2M MHC class I complex (positions specific for human HLA-G grafted onto the mouse H2Kd framework) SEQ ID NO: 29: Exemplary rat RT1A β2M MHC class I complex SEQ ID NO: 30: Exemplary human HLA-G / rat RT1A β2M MHC class I complex (positions specific for human HLA-G are grafted onto the rat RT1A framework) SEQ ID NO: 31: Linker and his tag SEQ ID NO: 32: Peptide SEQ ID NO: 33: Human kappa light chain constant region SEQ ID NO: 34: Human lambda light chain constant region SEQ ID NO: 35: IgG1 derived from human heavy chain constant region SEQ ID NO: 36: IgG1 derived from a human heavy chain constant region, containing the human mutations L234A, L235A and P329G SEQ ID NO: 37: IgG4 derived from human heavy chain constant region SEQ ID NO: 38: Heavy chain variable domain VH, HLA-G-0033 SEQ ID NO: 39: Light chain variable domain VL, HLA-G-0033

[0190] Specific embodiments of the present invention are listed below: 1. An isolated antibody that specifically binds to human HLA-G, said antibody binding to the human HLA-G β2M MHC I complex comprising SEQ ID NO:25. 2. An antibody according to embodiment 1 which inhibits binding of ILT2 to the monomeric HLA-G β2M MHC I complex. 3. An antibody according to embodiment 2 which inhibits the binding of ILT2 to the monomeric HLA-G β2M MHC I complex by more than 50% (when compared to binding without the antibody). 4. An antibody according to embodiment 2, which inhibits binding of ILT2 to monomeric and / or dimeric and / or trimeric HLA-G β2M MHC I complexes by more than 50% (in one embodiment more than 70%) (when compared to binding without the antibody). 5. An antibody according to any one of embodiments 1 to 4 which inhibits binding of ILT2 to JEG3 cells (human HLA-G above) (ATCC No. HTB36) by more than 50% (in one embodiment more than 80%) (as measured in a flow cytometry assay (FACS assay) (using fluorescence activated cell sorting)) (when compared to binding without the antibody). 6. An isolated antibody that specifically binds to human HLA-G, which binds to JEG3 cells (human HLA-G on) (ATCC No. HTB36) and inhibits binding of ILT2 to JEG3 cells (human HLA-G on) (ATCC No. HTB36) by more than 50% (in one embodiment more than 80%) compared to binding without the antibody (as measured in a flow cytometry assay (FACS assay) using fluorescence activated cell sorting). 7. An antibody according to any one of embodiments 1 to 6 that does not cross-react with (does not specifically bind to) a modified human HLA-G β2M MHC I complex comprising SEQ ID NO:26. 8. An antibody according to any one of embodiments 1 to 7, which does not cross-react (does not specifically bind to) the mouse H2Kd β2M MHC I complex comprising sequence number 27 and / or does not cross-react (does not specifically bind to) the rat RT1A β2M MHC I complex comprising sequence number 29. 9. An antibody according to any one of embodiments 1 to 8, which does not cross-react with (does not specifically bind to) the human HLA-A2 β2M MHC I complex comprising SEQ ID NO:21 and SEQ ID NO:19. 10. An isolated antibody that binds to human HLA-G, A) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:3; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6; or B) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:10; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:11; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:12; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:13; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:14. An antibody comprising: 11. An isolated antibody that binds to human HLA-G, A) (a) a VH domain comprising (i) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1, (ii) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2, and (iii) an HVR-H3 comprising an amino acid sequence selected from SEQ ID NO: 3; and (b) a VL domain comprising (i) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (ii) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and (iii) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6; or B) (a) a VH domain comprising (i) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 9, (ii) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 10, and (iii) an HVR-H3 comprising an amino acid sequence selected from SEQ ID NO: 11; and (b) a VL domain comprising (i) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12; (ii) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 13, and (iii) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14. Includes. 12. An isolated antibody that binds to human HLA-G, A) i) a VH sequence of SEQ ID NO: 7 and a VL sequence of SEQ ID NO: 8; or ii) Humanized variants of VH and VL of the antibody of i). Contains; or B) i) the VH sequence of SEQ ID NO: 15 and the VL sequence of SEQ ID NO: 16; or ii) Humanized variants of VH and VL of the antibody of i). An antibody comprising: 13. An isolated antibody that binds to human HLA-G, comprising: a) binds to the same epitope as an antibody comprising the VH sequence of SEQ ID NO: 7 and the VL sequence of SEQ ID NO: 8; or b) binds to the same epitope as an antibody comprising the VH sequence of SEQ ID NO: 15 and the VL sequence of SEQ ID NO: 16 antibody. 14. An anti-HLA-G antibody according to any one of embodiments 10 to 13, having the following characteristics: a) does not cross-react with (does not specifically bind to) a modified human HLA-G β2M MHC I complex comprising SEQ ID NO: 26; and / or b) does not cross-react with (does not specifically bind to) the human HLA-A2 β2M MHC I complex comprising SEQ ID NO:21 and SEQ ID NO:19; and / or c) does not cross-react with (does not specifically bind to) the mouse H2Kd β2M MHC I complex containing SEQ ID NO: 27; and / or d) does not cross-react with (does not specifically bind to) the rat RT1A β2M MHC I complex containing SEQ ID NO:29; and / or e) inhibiting binding of ILT2 to a monomeric HLA-G β2M MHC I complex (comprising SEQ ID NO: 25); and / or f) inhibits binding of ILT2 to a monomeric HLA-G β2M MHC I complex (comprising SEQ ID NO: 25) by more than 50% (in one embodiment by more than 70%) (when compared to binding without the antibody); and / or g) inhibits the binding of ILT2 to monomeric and / or dimeric and / or trimeric HLA-G β2M MHC I complexes (comprising SEQ ID NO: 25) by more than 50% (in one embodiment by more than 70%) (when compared to binding without the antibody); and / or h) inhibits (by more than 50%, in one embodiment by more than 80%) the binding of ILT2 to (human HLA-G on) JEG3 cells (ATCC No. HTB36) (when compared to binding without the antibody) (see Example 6); and / or i) binds to JEG3 cells (human HLA-G above) (ATCC No. HTB36) (see Example 5) and inhibits (by more than 50%, in one embodiment by more than 80%) the binding of ILT2 to JEG3 cells (human HLA-G above) (ATCC No. HTB36) (when compared to binding without the antibody) (see Example 6); and / or j) binds to the human HLA-G β2M MHC I complex (comprising SEQ ID NO: 25) and inhibits binding of ILT2 to monomeric and / or dimeric and / or trimeric HLA-G β2M MHC I complexes by more than 60% (compared to binding without antibody) and inhibits binding of ILT4 to dimeric and / or trimeric HLA-G β2M MHC I complexes by more than 50% (compared to binding without antibody) (see e.g. Example 4b). The antibody is independently characterized by 15. The antibody according to any one of embodiments 1 to 14, which is of the IgG1 isotype. 16. The antibody according to embodiment 15, which is of the IgG1 isotype comprising the mutations L234A, L235A and P329G (numbering according to EU index as per Kabat). 17. An isolated nucleic acid encoding an antibody according to any one of embodiments 1 to 16. 18. A host cell comprising the nucleic acid of embodiment 17. 19. A method for producing an antibody, comprising culturing a host cell according to embodiment 18 so that the antibody is produced. 20. The method of embodiment 19, further comprising recovering the antibody from the host cell. 21. A pharmaceutical formulation comprising an antibody according to any one of embodiments 1 to 16 and a pharma- ceutically acceptable carrier. 22. An antibody according to any one of embodiments 1 to 16 for use as a medicament. 23. An antibody according to any one of embodiments 1 to 16 for use in the treatment of cancer. 24. Use of an antibody according to any one of embodiments 1 to 16 in the manufacture of a medicament. 25. The use of embodiment 24, wherein the medicament is for the treatment of cancer. 26. A method for treating an individual having cancer, comprising administering to the individual an effective amount of an antibody of embodiment 1, 6 or 10 to 13. 27. A method for selecting an anti-HLAG antibody (e.g. according to embodiments 1 to 4), comprising: a) determining binding of an anti-HLAG antibody to a human HLA-G β2M MHC I complex comprising SEQ ID NO:25 by a surface plasmon resonance assay; b) determining the inhibition of ILT2 binding to monomeric and / or dimeric and / or trimeric HLA-G β2M MHC I complexes by each anti-HLAG antibody; and c) selecting an anti-HLAG antibody that inhibits the binding of ILT2 to monomeric HLA-G β2M MHC I complexes by more than 50% (in one embodiment by more than 80%) (when compared to binding without the antibody), or selecting an anti-HLAG antibody that inhibits the binding of ILT2 to monomeric and / or dimeric and / or trimeric HLA-G β2M MHC I complexes by more than 50% (in one embodiment by more than 70%) (when compared to binding without the antibody). The method includes: 28. A method for selecting an anti-HLAG antibody (e.g. according to embodiment 6), comprising: a) determining the binding of anti-HLAG antibodies to JEG3 cells (ATCC No. HTB36) in a flow cytometry assay (FACS assay) (using fluorescence activated cell sorting); b) determining the inhibition of ILT2 by each anti-HLAG antibody on JEG3 cells (ATCC No. HTB36) in a flow cytometry assay (FACS assay) (using fluorescence activated cell sorting); and c) selecting an anti-HLAG antibody that binds to JEG3 (ATCC No. HTB36) cells and inhibits the binding of ILT2 to JEG3 cells (ATCC No. HTB36) by more than 50% (in one embodiment by more than 80%) when compared to binding without the antibody; The method includes: EXAMPLES

[0191] Recombinant DNA Technology Standard methods were used to manipulate DNA as described in Sambrook, J. et al., Molecular cloning: A laboratory manual; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989. Molecular biology reagents were used according to the manufacturer's instructions.

[0192] Synthesis of genes and oligonucleotides The desired gene segments were prepared by chemical synthesis at Geneart GmbH (Regensburg, Germany). The synthesized gene fragments were cloned into E. coli plasmids for propagation / amplification. The DNA sequences of the subcloned gene fragments were confirmed by DNA sequencing. Alternatively, short synthetic DNA fragments were constructed by annealing chemically synthesized oligonucleotides or via PCR. The respective oligonucleotides were assembled by metabion GmbH (Planegg-Martinsried, Germany).

[0193] Description of basic / standard mammalian expression plasmids For expression of a desired gene / protein (e.g., a full-length antibody heavy chain, a full-length antibody light chain, or an MHC class I molecule, such as HLA-G, or an MHC class I molecule fused to a peptide and beta-2 microglobulin, such as HLA-G and / or beta-2 microglobulin fused to an HLA-G binding peptide), a transcription unit is used that contains the following functional elements: - the immediate early enhancer and promoter from human cytomegalovirus (P-CMV) containing intron A, -human heavy chain immunoglobulin 5'-untranslated region (5'UTR), -mouse immunoglobulin heavy chain signal sequence, - the gene / protein to be expressed (e.g. a full-length antibody heavy chain or an MHC class I molecule), and - bovine growth hormone polyadenylation sequence (BGH pA).

[0194] Besides the expression unit / cassette containing the desired gene to be expressed, a basic / standard mammalian expression plasmid contains: - an origin of replication from the vector pUC18 allowing replication of this plasmid in E. coli, and -The beta-lactamase gene that confers ampicillin resistance to E. coli Includes.

[0195] Protein quantification The protein concentration of the purified polypeptides was determined by measuring the optical density (OD) at 280 nm using the molar extinction coefficient calculated based on the amino acid sequence of the polypeptide.

[0196] Example 1 Generation of HLA-G chimeric molecules for screening and counterscreening Due to its high homology with other MHC I molecules (>98%), immunization with HLA-G molecules results in the generation of polyclonal sera composed of a mixture of MHC-I cross-reactive and truly HLA-G specific antibodies.

[0197] So far, no tools have been provided to select truly HLA-G specific antibodies that have no cross-reactivity to other human MHC-I (e.g. HLA-A) and furthermore have receptor blocking function.

[0198] The inventors have identified unique HLA-G positions in combination with positions required for structural matching and receptor interaction (ILT2 / 4 and KIR2DL4).

[0199] The unique and proximal position of human HLA-G was then "grafted" onto MHC class I complex molecules from various rodent species (eg, rat RT1A and mouse H2kd) to generate "chimeric" immunogens / screening antigens.

[0200] The antibodies generated were subjected to stringent screening for binding / specificity (and lack of binding / specificity to the counter antigen). Screening antigens: - rec. HLA-G expressed as a human HLA-G β2M MHC complex comprising SEQ ID NO: 25 - HLA-G specific sequences grafted onto rat RT-1 and mouse H2kd (SEQ ID NO: 28: human HLA-G / mouse H2Kd β2M MHC class I complex, in which the positions specific for human HLA-G are grafted onto the mouse H2Kd framework, and SEQ ID NO: 30: human HLA-G / rat RT1A β2M MHC class I complex, in which the positions specific for human HLA-G are grafted onto the rat RT1A framework) - HLA-G+ and PA-TU-8902 HLA-G+, which are native HLA-G MHC class I complex expressing cells (e.g. JEG3 cells) or the human HLA-G transfected cell line SKOV3. Screening counter antigens: - Other HLA-A sequences (HLA-A2 and HLA-G) combined with various peptides HlA-Aコンセンサス配列によるデグラフト ) (see, for example, SEQ ID NO: 22 (HLA-A2) and SEQ ID NO: 26, HLA-A consensus sequences on the HLA-G framework) - Counter antigens (MHC class I complex) from other species such as rat RT-1 and mouse H2kd (SEQ ID NO: 27 and SEQ ID NO: 29) - SKOV3 and PA-TU-8902, unmodified tumor cell lines characterized by the absence of HLA-G expression.

[0201] Design of chimeric HLA-G antigens for use in immunization and screening for the generation of HLA-specific antibodies (see FIG. 1): Design of a chimeric rat MHC I molecule (RT1-A) carrying the HLA-G unique position (SEQ ID NO: 30) for use in immunization of wild type (wt) and transgenic rats, or rabbits and mice, etc., and / or for use in screening assays: HLA-G unique positions were identified by alignment of 2579 HLA-A, 3283 HLA-B, 2133 HLA-C, 15 HLA-E, 22 HLA-F, and 50 HLA-G sequences in IMGT (available on Feb. 6, 2014). Those residues in HLA-G that are present in less than 1% (often ~0%) of the sequences in any of the three sequence sets HLA-A, HLA-B, and the combined set of HLA-C+HLA-E+HLA-F are referred to as HLA-G unique positions.

[0202] Four core HLA-G specific positions (two in alpha-1 and two in alpha-3) show no polymorphism in the set of HLA-G sequences, and no other HLA genes contain HLA-G specific residues at these positions (except 1×HLA-A for M100, 1×HLA-B for Q103, and 1×HLA-C for Q103).

[0203] The crystal structure of rat RT1-A (Rudolph, MG et al. J. Mol. Biol. 324: 975-990 (2002); PDB code: 1KJM) was superimposed onto the crystal structure of human HLA-G (Clements, CS et al. PROC. NATL. ACAD. SCI. USA 102: 3360-3365 (2005); PDB code: 1YDP). The structure of the alpha chain and the overall structure of the related beta-2-microglobulin are conserved.

[0204] HLA-G unique positions were identified in the RT1-A structure by comparison of sequence and structural alignments. In a first step, unique HLA-G positions that are exposed on the molecular surface of HLA-G and RT1-A and therefore accessible to antibodies were identified. Unique positions that are buried inside the folded protein were excluded from engineering. In a second step, structurally proximal residues were identified that also had to be exchanged to make the corresponding region "HLA-G-like", i.e. to generate a genuine HLA-G epitope containing the unique position, rather than generating a HLA-G / rat RT1-A chimeric epitope that would be artificial. All positions thus selected for mutation were analyzed for structural matches of the respective residues from HLA-G, in order to avoid possible localized perturbations of the molecular structure upon mutation.

[0205] A chimeric mouse MHC I molecule carrying the HLA-G unique locus (H2Kd) (SEQ ID NO:28) was similarly generated for use in immunization and / or for use in screening assays.

[0206] Design of an HLA-A based counter antigen by "de-grafting" the HLA-G unique position towards the HLA-A consensus sequence (SEQ ID NO:26) which is used as a counter antigen for screening. Unique positions from the multiple sequence alignment were analyzed in the crystal structure of human HLA-G (PDB code: 1YDP). First, positions that were not exposed on the HLA-G surface and therefore inaccessible to antibodies were excluded for engineering. Surface-exposed residues were then analyzed for feasibility of amino acid exchange (i.e., excluding possible local perturbations of the molecular structure when the relevant position is mutated). In total, 14 positions were validated for exchange. Amino acids at validated positions were mutated into the HLA-A consensus sequence derived from a multiple sequence alignment of 2579 HLA-A sequences downloaded from IMGT (available on February 6, 2014).

[0207] Generation of expression plasmids for soluble classical and non-classical MHC class I molecules The recombinant MHC class I genes encode an N-terminal extension fusion molecule consisting of the respective MHC class I molecule, beta-2 microglobulin, and a peptide to which the respective MHC class I molecule is known to bind.

[0208] The expression plasmid for the transient expression of soluble MHC class I molecules contained, in addition to the expression cassette for the soluble MHC class I molecule, an origin of replication from the vector pUC18, allowing replication of this plasmid in E. coli, and a beta-lactamase gene conferring ampicillin resistance in E. coli.

[0209] The transcription unit for soluble MHC class I molecules contained the following functional elements: - the immediate early enhancer and promoter from human cytomegalovirus (P-CMV) containing intron A, -human heavy chain immunoglobulin 5'-untranslated region (5'UTR), -mouse immunoglobulin heavy chain signal sequence, - an N-terminally truncated Staphylococcus aureus sortase A-encoding nucleic acid, and - bovine growth hormone polyadenylation sequence (BGH pA).

[0210] The amino acid sequences of mature soluble MHC class I molecules from various species are as follows: SEQ ID NO: 25: Exemplary human HLA-G β2M MHC class I complex SEQ ID NO: 26: Exemplary modified human HLA-G β2M MHC class I complex (HLA-G specific amino acids replaced by HLA consensus amino acids (=degrafted HLA-G, see also FIG. 1)) SEQ ID NO: 27: Exemplary mouse H2Kd β2M MHC class I complex SEQ ID NO: 28: Exemplary human HLA-G / mouse H2Kd β2M MHC complex (positions specific for human HLA-G grafted onto the mouse H2Kd framework) SEQ ID NO: 29: Exemplary rat RT1A β2M MHC class I complex SEQ ID NO: 30: Exemplary human HLA-G / rat RT1A β2M MHC complex (positions specific for human HLA-G are grafted onto the rat RT1A framework)

[0211] For the exemplary HLA-A2 β2M MHC class I complex used in the screen, the following components were used and the complex was expressed in E. coli and purified.

[0212] MHCI complex HLA-A2 / b2M (SEQ ID NO: 22 and 19) (both with an additional N-terminal methionine) + VLDFAPPGA peptide (SEQ ID NO: 32) + linker and his tag (SEQ ID NO: 31)

[0213] Example 2 Immunization campaigns a. Chimeric proteins (resistant to non-specific MHC-I / HLA and directed to a unique HLA-G locus) Balb / C mice obtained from Charles River Laboratories International, Inc. were used for immunization. Animals were housed in accordance with the AAALACi (Association for Assessment and Accreditation of Laboratory Animal Care International) Appendix A "Guidelines for accommodation and care of animals". All animal immunization protocols and experiments were approved by the Government of Upper Bavaria (permit numbers 55.2-1-54-2531-19-10 and 55.2-1-54-2532-51-11) and were performed in accordance with the German Animal Protection Act and Directive 2010 / 63 of the Council and of the European Parliament.

[0214] Balb / C mice (n=5) (age 6-8 weeks) received five immunizations with the chimeric H2Kd / HLA-G molecule (SEQ ID NO: 28 ("HLA-G-0006")) over the course of 4 weeks. Mice were anesthetized with a gas mixture of oxygen and isoflurane prior to each immunization. For the first immunization, 15 μg of protein in 20 mM His / HisCl, 140 mM NaCl, pH 6.0 was mixed with an equal volume of CFA (BD Difco, #263810) and administered subcutaneously (sc) at six sites along the back of the mouse proximal to the draining lymph nodes: two sites in the nape of the neck and two sites on each side of the groin and calf. An additional 15 μg of protein emulsified in RIBI adjuvant (Sigma-Aldrich, #S6322) was administered at six sites along the abdomen: two sites on each side of the axilla, groin, and thigh. Decreasing doses of booster antigen were given on days 7 (10 μg), 14 (5 μg), 21 (5 μg), and 28 (5 μg) in similar fashion, except that RIBI adjuvant was used only along the abdomen throughout. Three days after the last immunization, mice were euthanized and bilateral popliteal, superficial inguinal, axillary, and branchial lymph nodes were aseptically isolated and prepared for hybridoma production. Sera were tested for recombinant human HLA-G and immunogen-specific total IgG antibody production by ELISA after the third and fifth immunizations.

[0215] Another set of Balb / C mice (n=5), 6-8 weeks of age, received three immunizations with the chimeric H2Kd / HLA-G molecule (HLA-G-0006) over the course of 3 months. For the first immunization, 100 μg of protein dissolved in 20 mM His / HisCl, 140 mM NaCl (pH 6.0) was mixed with an equal volume of CFA (BD Difco, #263810) and administered intraperitoneally (ip). Booster immunizations were performed on days 28 and 56 in the same manner, but using complete Freund's adjuvant (IFA from BD Difco, #DIFC263910). Four to five weeks after the last immunization, mice were given approximately 25 μg of immunogen intravenously (iv) in sterile PBS, and 72 hours later, spleens were aseptically removed and prepared for hybridoma generation. Sera were tested against recombinant human HLA-G (SEQ ID NO: 25 ("HLA-G-0003")), and immunogen-specific chimeric H2Kd / HLA-G molecules (SEQ ID NO: 28 ("HLA-G-0006")), and counterscreened by ELISA after the third immunization using "degrafted" human HLA-G containing the consensus HLA-A specificity (SEQ ID NO: 26 ("HLA-G-0007")) and mouse H2kd protein (SEQ ID NO: 27 "HLA-G-0009")) total IgG antibody production.

[0216] B wild-type HLA-G protein For immunization, CD rats obtained from Charles River Laboratories International, Inc. were used. Animals were housed according to the AAALACi (Association for Assessment and Accreditation of Laboratory Animal Care International) Appendix A "Guidelines for accommodation and care of animals". All animal immunization protocols and experiments were approved by the Government of Upper Bavaria (permit number 55.2-1-54-2532-51-11) and were performed in accordance with the German Animal Protection Act and Directive 2010 / 63 of the Council and of the European Parliament.

[0217] CD rats (n=4), (age 6-8 weeks) received four immunizations with recombinant human HLA-G protein (SEQ ID NO: 25 ("HLA-G-0003")) over the course of 4 months. For the first immunization, 100 μg of protein dissolved in 20 mM His / HisCl, 140 mM NaCl, pH 6.0, was mixed with an equal volume of CFA (BD Difco, #263810) and administered intraperitoneally. Booster immunizations were performed on days 28, 56, and 84 in the same manner, but using complete Freund's adjuvant (IFA from BD Difco, #DIFC263910) throughout. Three to four weeks after the last immunization, rats were administered iv with approximately 75 μg of immunogen in sterile PBS, and 72 hours later, spleens were aseptically removed and prepared for hybridoma generation. Sera were tested by ELISA after the third and fourth immunization for recombinant HLA-G (SEQ ID NO: 25 ("HLA-G-0003"))-specific IgG1, IgG1a, IgG2b and IgG2c antibody production and counterscreened with "degrafted" human HLA-G with specificity at the consensus HLA-A position (SEQ ID NO: 26 ("HLA-G-0007")).

[0218] c. JEG3 cells (ATCC No. HTB36) (naturally expressing HLA-G) For immunization, CD rats obtained from Charles River Laboratories International, Inc. were used. Animals were housed according to the AAALACi (Association for Assessment and Accreditation of Laboratory Animal Care International) Appendix A "Guidelines for accommodation and care of animals". All animal immunization protocols and experiments were approved by the Government of Upper Bavaria (permit number AZ.55.2-1-542531-83-13) and were performed in accordance with the German Animal Protection Act and Directive 2010 / 63 of the Council and of the European Parliament.

[0219] Two sets of CD4+ rats (n=2), aged 6-8 weeks, were immunized five times (set A) or seven times (set B) with JEG-3 cells (ATCC HTB36) over the course of five (A) to seven (B) months, respectively. For the first immunization, 1x10^7 cells dissolved in sterile PBS were mixed with an equal volume of CFA (BD Difco, #263810) and administered intraperitoneally. Booster immunizations were performed on days 28, 56, 84, 112, 140 (set B only), and 168 (set B only) in the same manner, but using complete Freund's adjuvant (IFA from BD Difco, #DIFC263910) throughout. Three weeks after the last immunization, rats were given 100 μg of recombinant human HLA-G protein (SEQ ID NO: 25 ("HLA-G-0003")) iv in sterile PBS, and 72 hours later, spleens were aseptically removed and prepared for hybridoma production. Sera were tested for recombinant HLA-G (SEQ ID NO: 25 ("HLA-G-0003"))-specific IgG1, IgG1a, IgG2b and IgG2c antibody production by ELISA after the third, fifth and seventh immunizations, respectively, and counterscreened with "degrafted" human HLA-G with a specificity position in the consensus HLA-A (SEQ ID NO: 26 ("HLA-G-0007")).

[0220] d.JEG3 / DNA IMS (for booster effect) For immunization, CD rats obtained from Charles River Laboratories International, Inc. were used. Animals were housed according to the AAALACi (Association for Assessment and Accreditation of Laboratory Animal Care International) Appendix A "Guidelines for accommodation and care of animals". All animal immunization protocols and experiments were approved by the Government of Upper Bavaria (permit number AZ.55.2-1-542531-83-13) and were performed in accordance with the German Animal Protection Act and Directive 2010 / 63 of the Council and of the European Parliament.

[0221] CD40 rats (n=5) (age 6-8 weeks) were subjected to alternating plasmid DNA and cell-based immunizations over the course of three months. Plasmid DNA HLA-G-0030 (p17747), encoding human HLA-G as a single-chain molecule, and JEG-3 cells (ATCC HTB36), which naturally express HLA-G, were used for this purpose, respectively.

[0222] For the first immunization, animals were anesthetized with isoflurane and immunized intradermally (id) with 100 μg of plasmid DNA in sterile H2O applied to a single shaved site on the back near the animal's tail. After id application, the site was electroporated using the following parameters on an ECM 830 electroporation system (BTX Harvard Apparatus): 1000 V / cm for 0.1 ms, twice with 125 ms intervals, followed by 287.5 V / cm for 10 ms, four times also with 125 ms intervals. For the second immunization on day 14, animals received 1x10^7 cells dissolved in sterile PBS, which were mixed with an equal volume of CFA (BD Difco, #263810) and administered intraperitoneally after formation of a stable emulsion. Booster immunizations were performed on days 28 (DNA), 42 (cells), 56 (DNA), and 70 (cells) in the same manner, except that complete Freund's adjuvant (IFA from BD Difco, #DIFC263910) was used for cell immunizations throughout. Four weeks after the last immunization, rats were administered iv 100 μg of stable recombinant human HLA-G MHC class I protein (SEQ ID NO:25 ("HLA-G-0003")) in sterile PBS, and 72 hours later, spleens were aseptically removed and prepared for hybridoma generation. Sera were tested by ELISA after the third, fifth and sixth immunizations, respectively, for IgG1, IgG2a, IgG2b and IgG2c antibody production specific for stable recombinant human HLA-G MHC class I protein (SEQ ID NO: 25 ("HLA-G-0003")) and counterscreened with "degrafted" human HLA-G with specificity at the consensus HLA-A position (SEQ ID NO: 26 ("HLA-G-0007")).

[0223] All immunization strategies induced highly cross-reactive humoral immune responses that, when analyzed in an ELISA format using polyclonal sera from immunized animals, recognized HLA-G as well as the proteins used in the counterscreen (e.g. recombinant "degrafted" human HLA-G, the chimeric H2Kd / HLA-G molecule or the related human HLA-A2 molecule) (data not shown).

[0224] The binding characteristics and biological activity of the resulting anti-HLA-G specific antibodies were determined as described in the Examples below and compared to known reference antibodies.

[0225] Example 3 A) Binding of anti-HLA-G antibodies to soluble human HLA-G, soluble degrafted human HLA-G with HLA-A specific sequences, human HLA-A2, and / or rat mouse H2-Kd. Antibodies obtained from immunization were screened for their binding properties against human, rat and mouse HLA-G, chimeric, degrafted HLA-G and HLA-A. Each assay is described below. For testing human HLA-G, monomeric, dimeric and trimeric forms were used (see preparation below).

[0226] Dimerization / trimerization of human HLA-G MHC class I proteins The supernatant containing monomeric His-tagged soluble human HLA-G MHC class I protein (SEQ ID NO: 23) was loaded onto a 5 ml HisTrap HP column with Ni-Sepharose (GE Healthcare #17-5248-02) at a flow rate of 0.2 ml / min overnight at room temperature using an AKTA-FPLC. The column was then washed with 2% DPBS containing 0.5 M imidazole (Merck #8.14223.025) until baseline was reached. The column was then equilibrated with 10 mM DTT in 2% DPBS containing 0.5 M imidazole and incubated for 30 min at room temperature. DTT was washed off the column using PBS / 10 mM imidazole and the protein was eluted with a gradient of 2-100% DPBS containing 0.5 mM imidazole. After concentrating the eluate using Amicon-Ultra 15M / Ultracel 10K, the protein was incubated for 24 hours at room temperature followed by 48 hours at 4°C to allow dimerization / multimerization. Separation of dimers and trimers was then performed on a Superdex 200 HiLoad 16 / 60 (GE Healthcare #17-5175-01) and washed overnight with 0.5 M NaOH. The column was equilibrated with PBS and subsequently saturated with 10 mg / ml BSA. The dimers (fraction A9) and trimers (fraction A8) were then collected, aliquoted, and stored at -80°C until further use.

[0227] Human wild-type HLA-G binding ELISA Streptavidin-coated plates (Nunc, MicroCoat#11974998001) were coated with 25 μl / well of biotinylated human wild-type HLA-G at a concentration of 250 ng / ml and incubated overnight at 4° C. After washing (3×90 μl / well of PBST buffer), 25 μl of anti-HLA-G sample (diluted 1:3 in OSEP buffer) or reference antibody (G233, Thermo / Pierce#MA1-19449, 500 ng / ml) was added and incubated for 1 h at room temperature. After washing (3x90μl / well PBST buffer), 25μl / well of goat-anti-mouse H+L-POD (Biorad#170-6561, 1:2000 in OSEP) or donkey-anti-rabbit IgG POD (GE#NA9340V, 1:5000 in OSE) were added and incubated for 1h at room temperature on a shaker. For detection of rat IgG, goat-anti-rat IgG1-POD (Bethyl#A110-106P), goat-anti-rat IgG2a-POD (Bethyl#A110-109P) and goat-anti-rat IgG2b-POD (Bethyl#A110-111P) were added at 1:10000 in OSEP and incubated for 1h at room temperature on a shaker. After washing (6x90 μl / well PBST buffer), 25 μl / well TMB substrate (Roche, 11835033001) was added and incubated until OD 2-3. Measurements were performed at 370 / 492 nm on a Tecan Safire 2 instrument.

[0228] Starfish-grafted HLA-G binding ELISA with HLA-A specific sequences Streptavidin-coated plates (Nunc, MicroCoat#11974998001) were coated with 25 μl / well of biotinylated starfish grafted HLA-G at a concentration of 250 ng / ml and incubated overnight at 4° C. After washing (3×90 μl / well of PBST buffer), 25 μl of anti-HLA-G samples (diluted 1:3 in OSEP buffer) or rat serum (diluted 1:600 ​​in OSEP) were added and incubated for 1 hour at room temperature. After washing (3x90μl / well PBST buffer), 25μl / well of a mixture of goat-anti-rat IgG1-POD (Bethyl#A110-106P), goat-anti-rat IgG2a-POD (Bethyl#A110-109P) and goat-anti-rat IgG2b-POD (Bethyl#A110-111P) was added at 1:10000 in OSEP and incubated for 1 hour at room temperature on a shaker. After washing (6x90μl / well PBST buffer), 25μl / well of TMB substrate (Roche, 11835033001) was added and incubated until OD2-3. Measurements were performed at 370 / 492nm on a Tecan Safire 2 instrument.

[0229] Rat MHC I (RT1-A) binding ELISA Streptavidin-coated plates (Nunc, MicroCoat#11974998001) were coated with 25 μl / well of biotinylated rat MHC I (RT1-A) at a concentration of 250 ng / ml and incubated overnight at 4° C. After washing (3×90 μl / well of PBST buffer), 25 μl of anti-HLA-G samples (diluted 1:3 in OSEP buffer) or rat serum (diluted 1:600 ​​in OSEP) were added and incubated for 1 h at room temperature. After washing (3x90μl / well PBST buffer), 25μl / well of a mixture of goat-anti-rat IgG1-POD (Bethyl#A110-106P), goat-anti-rat IgG2a-POD (Bethyl#A110-109P) and goat-anti-rat IgG2b-POD (Bethyl#A110-111P) was added at 1:10000 in OSEP and incubated for 1 hour at room temperature on a shaker. After washing (6x90μl / well PBST buffer), 25μl / well of TMB substrate (Roche, 11835033001) was added and incubated until OD2-3. Measurements were performed at 370 / 492nm on a Tecan Safire 2 instrument.

[0230] HLA-A2 binding ELISA Streptavidin-coated plates (Nunc, MicroCoat#11974998001) were coated with 25 μl / well of biotinylated human HLA-A2 at a concentration of 250 ng / ml and incubated overnight at 4° C. After washing (3×90 μl / well of PBST buffer), 25 μl of anti-HLA-G samples (diluted 1:3 in OSEP buffer) or rat serum (diluted 1:600 ​​in OSEP) were added and incubated for 1 h at room temperature. After washing (3x90μl / well PBST buffer), 25μl / well of a mixture of goat-anti-rat IgG1-POD (Bethyl#A110-106P), goat-anti-rat IgG2a-POD (Bethyl#A110-109P) and goat-anti-rat IgG2b-POD (Bethyl#A110-111P) was added at 1:10000 in OSEP and incubated for 1 hour at room temperature on a shaker. After washing (6x90μl / well PBST buffer), 25μl / well of TMB substrate (Roche, 11835033001) was added and incubated until OD2-3. Measurements were performed at 370 / 492nm on a Tecan Safire 2 instrument.

[0231] Binding kinetics of anti-HLA-G antibodies The binding kinetics of anti-HLA-G antibodies to human HLA-G, human HLA-G degrafted and human HLA-A2 were investigated by surface plasmon resonance using a BIACORE T200 instrument (GE Healthcare). All experiments were performed at 25°C using PBS buffer (pH 7.4 + 0.05% Tween20) as the running buffer and PBS buffer (+ 0,1% BSA) as the dilution buffer. Anti-human Fc (JIR009-005-098, Jackson) or anti-rat Fc (JIR112-005-071, Jackson) or anti-mouse Fc (JIR115-005-071, Jackson) antibodies were immobilized on a Series S CM5 Sensor Chip (GE Healthcare) at pH 5.0 by using an amine coupling kit supplied by GE Healthcare. Anti-HLA-G antibodies were captured on the surface, resulting in a capture response of 50-200 RU. HLA-G molecules were injected at 30 μl / min over the surface at concentrations from 2.5 to 800 nM (dilution series of 2x1:2 and 4x1:3) for 180 seconds (association phase). The dissociation phase was monitored for 300-600 seconds by washing with running buffer. The surfaces were regenerated by injecting H3PO4 (0.85%) for 60+30 seconds for anti-human Fc capture antibodies, by injecting glycine (pH 1.5) for 60 seconds and glycine (pH 2.0) for 60 seconds for anti-rat Fc capture antibodies, and by injecting H3PO4 (0.85%) for 80+60 seconds for anti-mouse Fc capture antibodies. Bulk refractive index differences were corrected by subtracting the response obtained from a mock surface. Blank injections were subtracted (double reference). The resulting curves were fitted to a 1:1 Langmuir binding model using the BIAevaluation software.

[0232] Cross-blocking of anti-HLA-G antibodies Cross-blocking experiments of anti-HLA-G antibody binding to human HLA-G were investigated by surface plasmon resonance using a BIACORE T200 or B4000 instrument (GE Healthcare). All experiments were performed at 25°C using PBS buffer (pH 7.4 + 0.05% Tween 20) as the running buffer.

[0233] Anti-human Fab (GE-Healthcare, 28-9583-25) antibodies were immobilized on a Series S CM5 Sensor Chip (GE Healthcare) according to the supplier's protocol to capture antibodies from OMT rats containing human Ck domains. Anti-HLA-G antibodies were captured at a concentration of 15 μg / ml for 70 seconds. Wild-type HLA-G was injected at a concentration of 500 or 1000 nM for 60 seconds (30 μl / min). Wild-type rat antibodies were then injected at a concentration of 30 μg / ml for 90 seconds. The dissociation phase was monitored for 60 or 240 seconds by washing with running buffer. The surface was regenerated by injecting glycine (pH 1.5) for 60 seconds and an additional stabilization period of 90 seconds.

[0234] In another assay setup, anti-human Fab (GE-Healthcare, 28-9583-25) antibodies were immobilized on a Series S CM5 Sensor Chip (GE Healthcare) according to the supplier's protocol to capture antibodies from OMT rats containing human Ck domains. Anti-HLA-G antibodies were captured for 90 seconds at a concentration of 30 μg / ml. Unoccupied binding sites on the captured antibodies were blocked by injecting human IgG (JIR009-000-003) at a concentration of 500 μg / ml and a flow rate of 30 μl / min for 4×120 seconds. Wild-type HLA-G was injected for 90 seconds at a concentration of 500 nM (30 μl / min). A second antibody from OMT rats (human Ck domain) was then injected for 90 seconds at a concentration of 30 μg / ml. The dissociation phase was monitored for 240 seconds by washing with running buffer. The surface was regenerated by injecting glycine (pH 1.5) for 60 seconds followed by an additional stabilization period of 90 seconds.

[0235] TIFF0007592050000003.tif88170

[0236] The above table summarizes the binding of various rat anti-human HLA-G monoclonal antibodies from wild-type protein IMS. The relative EC50 values ​​[ng / ml] of the respective binding to rec wild-type monomeric, dimeric and trimeric HLA-G proteins assessed by ELISA are shown. The ELISA was set up by coating biotinylated wild-type HLA-G antigen on streptavidin plates. After incubation and washing steps, the respective antibodies were bound in a concentration range of 10 to 0 μg in 1:2 dilution steps. Detection of bound antibodies was performed with anti-Fc-antibody-POD conjugates. From the resulting binding curves, the EC50 values ​​were determined at the antibody concentration generating half-maximal signal. For non-biotinylated HLA-G dimeric and trimeric antigens, immobilization was performed by random coating on the assay plate.

[0237] Binding affinity of HLA-G antibodies to recombinant HLA-G (SEQ ID NO: 25) and to a control modified human HLA-G β2M MHC class I complex in which HLA-G specific amino acids have been replaced by HLA-A consensus amino acids (=degrafted HLA-G, SEQ ID NO: 26). ("-" indicates the absence of detectable binding) TIFF0007592050000004.tif132170

[0238] The above table summarizes the antibody affinity and t1 / 2 values ​​for wild-type and degrafted HLA-G assessed by surface plasmon resonance (Biacore) analysis. The binding kinetics of anti-HLA-G antibodies to human HLA-G, human HLA-G degrafted and human HLA-A2 were investigated by surface plasmon resonance using a BIACORE T200 instrument (GE Healthcare). All experiments were performed at 25°C using PBS buffer (pH 7.4 + 0.05% Tween20) as running buffer and PBS buffer (+ 0,1% BSA) as dilution buffer. Anti-human Fc (JIR009-005-098, Jackson) or anti-rat Fc (JIR112-005-071, Jackson) or anti-mouse Fc (JIR115-005-071, Jackson) antibodies were immobilized on a Series S CM5 Sensor Chip (GE Healthcare) at pH 5.0 by using an amine coupling kit supplied by GE Healthcare. Anti-HLA-G antibodies were captured on the surface, resulting in a capture response of 50-200 RU. HLA-G molecules were injected at 30 μl / min over the surface at concentrations from 2.5 to 800 nM (dilution series of 2x1:2 and 4x1:3) for 180 s (association phase). The dissociation phase was monitored for 300-600 s by washing with running buffer. The surfaces were regenerated by injecting H3PO4 (0.85%) for 60+30 seconds for anti-human Fc capture antibodies, by injecting glycine (pH 1.5) for 60 seconds and glycine (pH 2.0) for 60 seconds for anti-rat Fc capture antibodies, and by injecting H3PO4 (0.85%) for 80+60 seconds for anti-mouse Fc capture antibodies. Bulk refractive index differences were corrected by subtracting the response obtained from a mock surface. Blank injections were subtracted (double referenced). The resulting curves were fitted to a 1:1 Langmuir binding model using BIAevaluation software (-table above shows that there was no detectable binding).

[0239] The corresponding SPR sensorgram is shown in FIG.

[0240] In further experiments, the following reference antibodies (obtained from various commercial vendors) were compared for binding to monomeric human HLA-G MHC I (SEQ ID NO: 23 ("HLA-G-0003")) and "degrafted" human HLA-G with consensus HLA-A specificity positions (SEQ ID NO: 24 ("HLA-G-0007")): MEM / G9, 87G, G233, 2A12, 4H84, 5A6G7, 6D463, 9-1F10, MEM-G / 1, MEM-G / 11, MEM-G / 2 and MEM-G / 4 ("-" indicates the absence of detectable binding). TIFF0007592050000005.tif122170TIFF0007592050000006.tif121170

[0241] Interestingly, many of the antibodies measured, including antibody 87G, did not show any specific binding to monomeric human HLA-G MHC I (SEQ ID NO: 25 ("HLA-G-0003")). Binding to oligomeric forms of HLA-G as described in the literature could be avidity resulting from an increase in binding sites for the oligomeric form.

[0242] 7.7E -09 Antibody MEM / G9 with a binding affinity K value of M, 2.0E -08 Antibodies G233 and 1.2E with KD values ​​of M -08 Only MEM-G / 11, which has a binding affinity KD value of M, showed binding to the monomeric wild-type human HLA-G MHC I complex. However, one of these antibodies, MEM-G / 11, also showed some binding / cross-reactivity to the HLA-A consensus on HLA-G degrafted (SEQ ID NO: 26). In addition, another antibody (MEM / G9) also showed stronger non-specific binding to the HLA-A consensus on HLA-G degrafted (SEQ ID NO: 26).

[0243] Example 4 Receptor blockade (by monomeric, dimeric, and trimeric HLA-G) a) Biochemical comparison of anti-HLA-G antibodies with respect to blocking properties of ILT2 and -4 Streptavidin-coated plates (Nunc, MicroCoat#11974998001) were coated with 25 μl / well of biotinylated human wild-type HLA-G at a concentration of 500 ng / ml and incubated overnight at 4° C. After washing (3×90 μl / well of PBST buffer), 25 μl of anti-HLA-G samples were added starting from 8 μg / ml and then serially diluted 1:3 and incubated for 1 hour at room temperature. After washing (3×90 μl / well of PBST buffer), 25 μl / well of c-myc-tagged recombinant ILT-2 receptor was added at a concentration of 150 ng / ml and incubated for 1 hour at room temperature. After washing (3x90 μl / well PBST buffer), 25 μl / well goat-anti-c-myc-POD (Bethyl#A190-104P, 1:7000 in OSE) was added and incubated for 1 h at room temperature on a shaker. After washing (6x90 μl / well PBST buffer), 25 μl / well TMB substrate (Roche, 11835033001) was added and incubated until OD2-3. Measurements were performed at 370 / 492 nm on a Tecan Safire 2 instrument.

[0244] TIFF0007592050000007.tif109170

[0245] The above table summarizes the blocking of the interaction between recHLA-G protein (monomeric and oligomeric) and its receptors ILT2 and ILT4, assessed by ELISA. The % inhibition of HLA-G / receptor interaction (for ILT2 and ILT4) and the relative IC50 values ​​[nM] for neutralization of HLA-G / receptor interaction (when monomeric (M), dimeric (D) or trimeric (T) HLA-G protein was used) are shown. The less pronounced inhibition of ILT4 is due to the predominant β-2M-dependent interaction of this receptor.

[0246] The ELISA was set up by coating the biotinylated antigen wild type HLA-G on streptavidin plates. After incubation and washing steps, the respective antibodies were bound in a concentration range of 8 to 0 μg in 1:3 dilution steps. C-myc tagged ILT-2 or -4 receptors were added to the HLA-G-antibody complexes. After incubation and washing steps, detection of bound receptors was performed with anti-cmyc-antibody-POD conjugates. From the resulting inhibition curves, IC50 values ​​were determined at the antibody concentration producing half-maximal inhibition. For non-biotinylated HLA-G dimer and trimer antigens, immobilization was performed by random coating on the assay plates.

[0247] b) Biochemical comparison of anti-HLA-G antibodies with respect to blocking properties of ILT2 and -4 using different assay configurations The ELISA was set up by coating Fc-tagged ILT2 and ILT4, respectively, to Maxisorp microtiter plates. After incubation and washing steps, the respective antibodies were added at a concentration of 100 nM. Soluble His-tagged monomeric, dimeric or trimeric HLA-G was added to the wells. After incubation and washing steps, detection of bound receptor was performed with an anti-His-antibody-POD conjugate. The percentage of inhibition was calculated in comparison to the values ​​obtained from wells containing ILT2 / 4+HLA-G (monomeric, dimeric or trimeric) and no anti-HLA-G or ILT2 / 4 antibodies (100% binding = 0% inhibition).

[0248] TIFF0007592050000008.tif61170

[0249] The above table summarizes the blocking of the interaction between recHLA-G protein (monomer and oligomer) and its receptors ILT2 and ILT4, assessed by ELISA. The % inhibition of HLA-G / receptor interaction is shown (for ILT2 and ILT4). The less pronounced inhibition of ILT4 is due to the primary β-2M dependent interaction of this receptor.

[0250] The bar graph below shows the % inhibition achieved by the anti-HLA-G antibodies described herein in comparison to commercially available antibodies as shown in the graph. The commercially available HLA-G antibodies 87G, MEM / G09 and G233 do not block HLA-G / ILT2 or ILT4 interactions as efficiently as the antibodies described herein. Furthermore, the commercially available antibodies, in some cases, upon binding, result in increased binding of HLA-G to ILT2 or ILT4.

[0251] Example 5 Binding of anti-HLA-G antibodies to cells a) Cell surface HLA-G binding ELISA 25 μl / well of JEG3 cells (naturally expressing HLA-G, 20000 cells / well), Skov-3 cells, or Skov-3 cells expressing recombinant HLA-G on the cell surface (both 10000 cells / well) were seeded in tissue culture treated 384-well plates (Corning, 3701) and incubated overnight at 37° C. The next day, 12.5 μl of anti-HLA-G samples (final dilution 1:3) were added and incubated for 2 hours at 4° C. Cells were fixed by adding 50 μl / well of glutaraldehyde to a final concentration of 0.05% (Sigma Cat. No: G5882; Lot No.: 056K5318). After washing (3x90μl / well PBST buffer), 25μl / well of goat-anti-mouse H+L-POD (Biorad#170-6561, 1:2000 in OSEP) or donkey-anti-rabbit IgG POD (GE#NA9340V, 1:5000 in OSE) were added and incubated for 1h at room temperature on a shaker. For detection of rat IgG, goat-anti-rat IgG1-POD (Bethyl#A110-106P), goat-anti-rat IgG2a-POD (Bethyl#A110-109P) and goat-anti-rat IgG2b-POD (Bethyl#A110-111P) were added at 1:10000 in OSEP and incubated for 1h at room temperature on a shaker. After washing (4x90 μl / well PBST buffer), 25 μl / well TMB substrate (Roche, 11835033001) was added and incubated until OD 2-3. Measurements were performed at 370 / 492 nm on a Tecan Safire 2 instrument.

[0252] TIFF0007592050000009.tif66170

[0253] The above table summarizes the binding of various rat anti-human HLA-G monoclonal antibodies to HLA-G expressed on various cells and cell lines, assessed by FACS analysis. Binding is given to either JEG3 tumor cells that naturally express HLA-G or to Skov3 or PA-TU-8902 transfectants and their respective parental untransfected cells.

[0254] b) Binding of HLA-G antibodies to native or recombinant HLA-G expressed on cells (assessed by FACS analysis) For flow cytometry analysis, cells were stained with anti-HLA-G mAbs at 4° C. Briefly, 25 μl / well of each cell suspension (5×10 4 Cells / well) were transferred to a polypropylene 96-well V-bottom plate and pre-chilled in a refrigerator at 5°C for 10 min. Anti-HLA-G samples were diluted 2x in staining buffer to a starting concentration of 80 μg / ml. 4x serial dilutions of antibodies were performed and 25 μl / well of antibody solution were added to the prepared cells and incubated for 1 h at 5°C. Cells were washed twice with 200 μl / well of staining buffer and centrifuged at 300g for 3 h. For detection, fluorescently labeled anti-species antibodies (goat anti-rat IgG(H+L)) conjugated to Alexa 488 (Life technologies# A11006) or goat anti-mouse IgG(H+L) (Life technologies# A11001) were diluted to 20 μg / ml in staining buffer and cell pellets were resuspended in 50 μl / well of detection antibody. After 1 hour of incubation at 5°C, the cells were washed again twice with staining buffer, resuspended in 70 μl of staining buffer, and measured on a FACS Canto II.

[0255] An exemplary FACS staining of clone HLA-G#0032-0037 is shown in the FACS overlay in FIG.

[0256] Example 6 Anti-HLA-G antibodies inhibit / modulate the interaction of recombinant ILT2 with HLA-G naturally expressed on JEG3 cells. For the analysis, JEG3 cells (ATCC HTB36) were stained with ILT2-Fc fusion protein with or without preincubation with various anti-HLA-G antibodies (control = no inhibition). For preincubation with anti-HLA-G antibodies, 25 μl / well of cell suspension was transferred to a polypropylene 96-well V-bottom plate and pre-chilled for 10 min at 4°C. Anti-HLA-G antibodies or reference antibodies (G233, MEM-G / 9 or 87G) were diluted in staining buffer to a 2x concentration of 20 μg / ml and 25 μl / well of antibody solution was added to the prepared cells and incubated for 1 h at 5°C. Cells were washed twice with 200 μl / well of staining buffer, centrifuged at 300 g for 3 min and finally resuspended in 25 μl / well of staining buffer.

[0257] Detection of human ILT2-Fc chimeric protein (RD#2017-T2-050) on a) JEG3 cells pre-incubated with anti-HLA-G mAb or b) untreated JEG3 cells as a reference was determined as follows: Briefly, ILT2-Fc or control human IgG (Jackson-Immuno-Research# 009-000-003) was diluted in staining buffer to a concentration of 20 μg / ml, twice that of (ILT2), and 25 μl / well of ILT2-Fc protein solution was added to the prepared cells and incubated for 2 hours at 5°C. Cells were washed again twice with 200 μl / well staining buffer and human ILT2-Fc protein was detected using fluorescently labeled anti-human IgG Fc-gamma specific antibody (F(ab')2 fragment goat anti-human IgG, Fcγ fragment specific FITC, Jackson-Immuno-Research# 109-096-008) at 10 μg / ml in staining buffer. Cell pellets were resuspended in 50 μl / well detection antibody. After 1 hour incubation at 5° C., cells were washed twice with staining buffer, resuspended in 70 μl and measured on a FACS Canto II to determine binding of ILT2 to JEG3 cells.

[0258] As a control, anti-HLA-G antibodies bound to JEG-3 pre-incubated cells were detected by using anti-species antibodies (goat anti-rat IgG(H+L) conjugated to Alexa 488 (Life technologies, # A11001) or goat-anti-mouse IgG(H+L)-Alexa 488 (Life technologies # A11006) at a concentration of 10 μg / ml.

[0259] The graph in Figure 6 shows the respective abilities of different HLA-G antibodies to modulate the interaction and binding of recombinant ILT2 to HLA-G naturally expressed on JEG3 tumour cells.

[0260] The table below summarizes the experimental results. Binding of anti-HLA-G antibodies to JEG3 cells is indicated from + (= weak binding) to +++ (= strong binding). The ability of anti-HLA-G antibodies to inhibit / block or increase the binding of ILT2 to JEG3 cells expressing HLA-G. In the last column the binding of recombinant ILT2 to the cells or its inhibition / blocking is shown / quantified (staining of ILT2-Fc in the absence of anti-HLA-G antibodies was set to 100% binding, i.e. 0% inhibition. Negative values ​​indicate increased binding. Differences in staining signals less than 5% were not significant and were classified as "no effect"):

[0261] TIFF0007592050000010.tif167170

[0262] Example 7 Monocyte cytokine restoration assay (after HLA-G-mediated suppression) For the functional characterization of the various rat anti-human HLA-G monoclonal antibodies, the following co-culture assay of HLA-G expressing cells with monocytes was used. Peripheral human monocytes were isolated from the blood of healthy donors. Briefly, blood was collected in tubes containing anticoagulant and diluted 1:2 with PBS. To isolate peripheral blood mononuclear cells (PBMCs), 30 ml of the mixture was transferred to each Leucosep tube pre-filled with separation medium. The PBMC-specific band was collected after 12 min of centrifugation (1200xg without braking), washed three times with PBS and centrifuged at 300xg for 10 min. Finally, the cell pellet was resuspended in MACS buffer from Miltenyi and human monocytes were isolated from PBMCs via magnetic sorting with Miltenyi's Human Monocyte Isolation Kit II (#130-091-153) according to the manufacturer's instructions (negative sorting). Isolated monocytes were resuspended in primary cell culture medium (RPMI 1640, PAN#P04-17500 supplemented with 10% FCS, Gibco#10500; 2 mM L-glutamine, Sigma#G7513; 1 mM sodium pyruvate, Gibco#11360; MEM non-essential amino acids, Gibco#11140; 0,1 mM 2-mercaptoethanol, Gibco#31350; MEM vitamins, Gibco#11120; penicillin streptomycin, Gibco#15140) at a density of 5x10e5 cells / ml. CD14 + CD16 +Cell enrichment was monitored by flow cytometry and cells were analyzed for ILT2 and ILT4 expression. For co-culture assays of enriched monocytes with HLA-G expressing cells, JEG-3 cells were seeded in 96-well flat-bottom tissue culture plates at 8x10e3 cells / well in 100 μl in JEG-3 culture medium (MEM Eagle with EBSS and L-glutamine, PAN#P04-00509 supplemented with 10% FCS, Gibco#10500; 1 mM sodium pyruvate, Gibco#11360; MEM non-essential amino acids Gibco#11140) the day before the assay and overlaid on the day of the assay. Adherent JEG-3 cells were pre-incubated with anti-HLA-G antibodies serially diluted 4-fold in primary cell culture medium. Therefore, the supernatant from the adherent JEG-3 cells was removed, 50 μl / well of the prepared antibody solution was added and incubated for 1 hour at 37°C and 5% CO2 in a humidified atmosphere. Human monocytes were added to the JEG-3 cells pre-incubated with anti-HLA-G antibodies at 2.5x10e4 human monocytes / well in 50 μl of primary cell culture medium and the co-culture was incubated overnight (approximately 18-20 hours) at 37°C and 5% CO2 in a humidified atmosphere. The next day, LPS stimulation with 50 ng / ml LPS was performed for 7 hours, after which the co-culture supernatant was harvested. The concentration of TNF-alpha in the co-culture supernatant was determined using the Human TNF-alpha ELISA Ready-SET-Go!® from eBioscience (#88-7346-88).

[0263] The table below summarizes the functional properties of given HLA-G antibody candidates.

[0264] Functional anti-HLA-G antibodies are able to restore suppressed immune responses (ie, restore LPS-induced TNFα production by monocytes in co-culture with HLA-G expressing cells).

[0265] TIFF0007592050000011.tif79170

Claims

1. A method for selecting an isolated antibody that specifically binds to human HLA-G from anti-HLAG antibodies, comprising the steps of: a) determining the binding of each anti-HLAG antibody to a human HLA-G β2M MHC I complex comprising SEQ ID NO:25 by a surface plasmon resonance assay; b) determining the binding of each anti-HLAG antibody to "degrafted" human HLA-G having the consensus HLA-A specificity position comprising SEQ ID NO:26 by surface plasmon resonance assay; c) selecting an antibody that binds to a human HLA-G β2M MHC I complex comprising SEQ ID NO:25 and does not cross-react with a modified human HLA-G β2M MHC I complex comprising SEQ ID NO:26; d) determining the inhibition of ILT2 binding to monomeric and / or dimeric and / or trimeric HLA-G β2M MHC I complexes by each anti-HLAG antibody; e) selecting an anti-HLAG antibody that inhibits the binding of ILT2 to the monomeric HLA-G β2M MHC I complex by more than 50% compared to binding without the antibody, or selecting an anti-HLAG antibody that inhibits the binding of ILT2 to the monomeric and / or dimeric and / or trimeric HLA-G β2M MHC I complex by more than 50% compared to binding without the antibody; and f) isolating the antibodies selected by steps c) and e) as isolated antibodies that specifically bind to human HLA-G. A method comprising:

2. A method for selecting an isolated antibody that specifically binds to human HLA-G from anti-HLAG antibodies, comprising: a) determining the binding of each anti-HLAG antibody to JEG3 cells (ATCC No. HTB36) in a flow cytometry assay; b) determining the inhibition of ILT2 by each anti-HLAG antibody on JEG3 cells (ATCC No. HTB36) in a flow cytometry assay; and c) selecting anti-HLAG antibodies that bind to JEG3 (ATCC No. HTB36) cells and inhibit the binding of ILT2 to JEG3 cells (ATCC No. HTB36) by more than 50%, preferably more than 80%, when compared to binding without the antibody; The method of claim 1 further comprising:

3. A method for producing an isolated antibody that specifically binds to human HLA-G from anti-HLAG antibodies, comprising selecting an anti-HLAG antibody by the method of claim 1 or 2.

Citation Information

Patent Citations

  • JPP7108612B